КОМПОЗИЦИИ НА ОСНОВЕ СИАЛИРОВАННЫХ ГЛИКОПРОТЕИНОВ И ИХ ПРИМЕНЕНИЕ

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2016 138 790 A (51) МПК A61K 31/7012 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2016138790, 05.03.2015 (71) Заявитель(и): УЛЬТРАДЖИНИКС ФАРМАСЬЮТИКАЛ ИНК. (US) Приоритет(ы): (30) Конвенционный приоритет: 05.03.2014 US 61/948,421; 10.02.2015 US 62/114,313 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 05.10.2016 US 2015/018859 (05.03.2015) (87) Публикация заявки PCT: A WO 2015/134696 (11.09.2015) Адрес для переписки: 123242, Москва, пл. Кудринская, д. 1, а/я 35, "Михайлюк, Сороколат и партнеры - патентные поверенные" R U (57) Формула изобретения 1. Композиция, содержащая рекомбинантный гликопротеин, причем рекомбинантный гликопротеин представляет собой β-глюкуронидазу человека и имеет степень сиалирования, которая составляет по меньшей мере 0,7 моль/моль рекомбинантного гликопротеина. 2. Композиция по п. 1, отличающаяся тем, что рекомбинантный гликопротеин имеет высокий уровень маннозо-6-фосфатных (М6Ф) фрагментов. 3. Композиция по п. 1, отличающаяся тем, что рекомбинантный гликопротеин имеет степень сиалирования, которая составляет по меньшей мере 1 моль/моль, и высокий уровень фрагментов М6Ф, который составляет по меньшей мере 10 мол.% от общего количества гликана рекомбинантного гликопротеина. 4. Композиция по п. 1, отличающаяся тем, что рекомбинантный гликопротеин имеет высокий уровень фрагментов М6Ф, а зависимая от М6Ф полумаксимальная концентрация составляет не более чем 3 нМ рекомбинантного гликопротеина в фибробластные клетки человека. 5. Препарат совокупности рекомбинантных гликопротеинов, причем рекомбинантный белок представляет собой β-глюкуронидазу человека и по меньшей мере 10 % совокупности рекомбинантных гликопротеинов сиалированы. 6. Препарат по п. 5, отличающийся тем, что рекомбинантный белок имеет степень Стр.: 1 A 2 0 1 6 1 3 8 7 9 0 (54) КОМПОЗИЦИИ НА ОСНОВЕ СИАЛИРОВАННЫХ ГЛИКОПРОТЕИНОВ И ИХ ПРИМЕНЕНИЕ 2 0 1 6 1 3 8 7 9 0 (86) ...

PROCESS FOR THE ISOLATION OF FERMENTATION PRODUCTS

PROCESS FOR THE ISOLATION OF FERMENTATION PRODUCTS

The invention provides a process for the production of ethanol and a protein or peptide which is heterologous to yeast which comprises fermenting an aqueous carbohydrate-containing medium with an industrial yeast strain which has been genetically modified to be capable of expressing a heterologous protein or peptide, under conditions such that the yeast multiplies but no expression of the said heterologous protein or peptide takes place, recovering the ethanol so-formed, inducing expression of the said protein or peptide by the yeast, and obtaining the said heterologous protein or peptide therefrom. The process may be applied to the industrial production of alcoholic beverages such as beer or distilled alcohol. The yeast inevitably obtained as a by-product in the process has improved value because it provides a source of the heterologous protein or peptide. Heterologous protein and peptides which may be produced by the new process include enzymes such as beta-lactamase, beta-glucanase and ...

Novel exo-(1-4)- beta-D galactanase

AGARASE AND GENE FOR IT

BETA GALACTOSIDASE ONE WITH TRANSGALACTOSYLIERUNGSAKTIVITÄT

PROCEDURE FOR THE ISOLATION OF FERMENTATION PRODUCTS.

ENZYME WITH GALAKTANASEAKTIVITÄT

PROCEDURE FOR THE ADMINISTRATION OF FAVORABLE COMPOSITIONS ON THE HAIR FOLLICLES

Method for killing microorganism

Provided is a technique for enabling the easy storage and utilization of a solution that contains cells of a microorganism and has an enzymatic activity. The technique is a method for killing a microorganism in a solution that contains cells of the microorganism and has an enzymatic activity while keeping the enzyme titer of the solution, characterized by comprising adjusting the pH value of the solution and then heating the pH-adjusted solution. Alternatively, the technique is a method for killing a microorganism in a solution that contains cells of the microorganism and has an enzymatic activity while keeping the enzyme titer of the solution, characterized by comprising adding a carbohydrate to the solution and then heating the carbohydrate-added solution.

PROCESS FOR THE CULTIVATION OF PLANT CELLS IN VITRO

POLYPEPTIDES, HAVING ACTIVITY TRANSGALAKTOZILIROVANIYa

PRODUCT ENZYMATIC CONTAINING OF THE BETA-GALACTOSIDASE, MICRO-ORGANISM AND PROCEEDED FOR SA PREPARATION AND USE OF THIS PRODUCT.

La bêta-galactosidase est obtenue par culture d'un micro-organisme appartenant au groupe taxonomique représenté par la culture-type NRLL B-11, 229. L'enzyme isolé des cellules microbiennes résiste à la chaleur et à l'inhibition par le lactose et ses produits d'hydrolyse, de sorte qu'il peut être utilisé avantageusement pour convertir du petit-lait par exemple en un sirop contenant du glucose et du galactose. Beta-galactosidase is obtained by culture of a microorganism belonging to the taxonomic group represented by the standard culture NRLL B-11, 229. The enzyme isolated from microbial cells resists heat and inhibition by lactose and its hydrolysis products, so that it can be advantageously used to convert whey for example into a syrup containing glucose and galactose.

GENE INSULATES CODING FOR THE LAMBDA-CARRAGHENASE AND THE LAMBDA-CARRAGHENASERECOMBINANTE OBTAINED USING THIS GENE

L'invention a pour objet un gène codant pour un polypeptide présentant une activité carraghénase λ c'est-à-dire une enzyme capable de dégrader les carraghénanes. L'invention a également pour objet un procédé de production du susdit polypeptide sous forme recombinante par mise en oeuvre des techniques de génie génétique en utilisant le susdit gène. Enfin l'invention vise l'utilisation du susdit polypeptide recombinant pour la dégradation des polysaccharides de type carraghénane permettant d'obtenir des fractions oligosaccharidiques.

PREPARATION AND USE OF BIOFILM-DEGRADING, MULTIPLE-SPECIFICITY, HYDROLYTIC ENZYME MIXTURES

The present invention is directed to the production and use of custom tailored, bacterial enzyme mixtures or components thereof for degrading biofilms in both industrial and therapeutic applications. The industrial applications include but are not limited to the use of biofilm-degrading, multiple specificity, hydrolytic enzyme mixtures for removing or preventing the formation of biofilms in water cooling towers, industrial process piping, heat exchangers, in food processing or food preparation, in potable water systems, reservoirs, swimming pools, or related sanitary water systems, and on membranes such as those used for desalinization, industrial processes, or related applications. The therapeutic applications include but are not limited to the use of therapeutically-useful, multiple-specificity, hydrolytic enzyme mixtures for the prevention or treatment of dental caries, periodontal disease, cystic fibrosis or the complications or symptoms of cystic fibrosis, removal of biofilms from ...

Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures

The present invention relates to isolated structures containing degradative enzymes produced from a marine organism. The enzymes produced are based on the carbon source upon which the marine organism is growing. The enzymes are found in structures that can be isolated such that the degradative enzymes are easily harvested.

GALACTANASE VARIANTS

The present invention relates to variants of Glycoside Hydrolase family 53 galactanases, e.g., variants of the galactanases from strains of Yersinia, Aspergillus, Humicola, Meripilus, Myceliophthora, Thermomyces, Bacillus, Bifidobacterium, Cellvibrio, Clostridium, Pseudomonas, Thermotoga, or Xanthomonas.

Fungal high-level protein production system

Provided are cells having an increased protein production characterized in that said cell comprises modified SUMOylation, a process for producing such a cell or expression system and the use of such a cell in producing a protein of interest.

Patent RU2016138790A3

`”ВУ“” 2016138790” АЗ Дата публикации: 23.08.2018 Форма № 18 ИЗ,ПМ-2011 Федеральная служба по интеллектуальной собственности Федеральное государственное бюджетное учреждение ж 5 «Федеральный институт промышленной собственности» (ФИПС) ОТЧЕТ О ПОИСКЕ 1. . ИДЕНТИФИКАЦИЯ ЗАЯВКИ Регистрационный номер Дата подачи 2016138790/15(061836) 05.03.2015 РСТЛО52015/018859 05.03.2015 Приоритет установлен по дате: [ ] подачи заявки [ ] поступления дополнительных материалов от к ранее поданной заявке № [ ] приоритета по первоначальной заявке № из которой данная заявка выделена [ ] подачи первоначальной заявки № из которой данная заявка выделена [ ] подачи ранее поданной заявки № [Х] подачи первой(ых) заявки(ок) в государстве-участнике Парижской конвенции (31) Номер первой(ых) заявки(ок) (32) Дата подачи первой(ых) заявки(ок) (33) Код страны 1. 61/948,421 05.03.2014 05 2. 62/114,313 10.02.2015 05 Название изобретения (полезной модели): [ЖХ] - как заявлено; [ ] - уточненное (см. Примечания) КОМПОЗИЦИИ НА ОСНОВЕ СИАЛИРОВАННЫХ ГЛИКОПРОТЕИНОВ И ИХ ПРИМЕНЕНИЕ Заявитель: УЛЬТРАДЖИНИКС ФАРМАСЬЮТИКАЛ ИНК., 05 2. ЕДИНСТВО ИЗОБРЕТЕНИЯ ( ] соблюдено [Х] не соблюдено. Пояснения: см. Примечания 3. ФОРМУЛА ИЗОБРЕТЕНИЯ: [Х] приняты во внимание все пункты (см. Примечания) [ ] приняты во внимание следующие пункты: [ ] принята во внимание измененная формула изобретения (см. Примечания) 4. КЛАССИФИКАЦИЯ ОБЪЕКТА ИЗОБРЕТЕНИЯ (ПОЛЕЗНОЙ МОДЕЛИ) (Указываются индексы МПК и индикатор текущей версии) Аб/1К 38/47 (2006.01) Аб1Р 3/00 (2006.01) С12М 15/67 (2006.01) 5. ОБЛАСТЬ ПОИСКА 5.1 Проверенный минимум документации РСТ (указывается индексами МПК) Аб1К 38/00, 38/43, 38/47, Аб1Р3З/00, С12М№М15/00, 15/67 5.2 Другая проверенная документация в той мере, в какой она включена в поисковые подборки: 5.3 Электронные базы данных, использованные при поиске (название базы, и если, возможно, поисковые термины): РУ/РТ, ЕАРАТГУ, Езрасепе, Соое, МСВТ, РАТЕМТСОРЕ, Ра еагсв, РиБМеа, КУРТО, РМЖ 6. ДОКУМЕНТЫ, ОТНОСЯЩИЕСЯ К ...

ZELLULOSEBINDENDE FUSIONSPROTEINE

Method for preserving polypeptides using a sugar and polyethyleneimine

Galactosidase with alph-galactosyltransferase activity

Method of preparation of cloning vector

A method of producing a cloning vector including the steps of, obtaining a nucleic acid molecule with a repeated sequence, and, cutting the nucleic acid molecule to obtain a length of nucleic acid posessing at least part of the said repeated sequence.

CELLULOSE-BINDING FUSION PROTEINS

CONTROLLABLE INTERMEDIATE SEQUENCES ABSTENTIONS MODIFIED PROTEINS AND PROCEDURES FOR THE THEIR PRODUCTION

ENDOGLUKANASE OF THERMOTOGA

AGARASE AND GENE FOR IT

GALAKTOSIDASE WITH ALPHA GALAKTOSYLTRANSFERASEAKTIVITÄT

KLONIERTES STREPTOMYCES BETA GALAKTOSIDASEPROMOTER FRAGMENT.

Bacterial galactanases and use thereof

Method for delivering beneficial compositions to hair follicles

Process for the production of cells which are capable of converting arabinose

The invention relates to a process for the production of cells which are capable of converting arabinose, comprising the following steps: a)Introducing into a host strain that cannot convert arabinose, the genes AraA, araB and araD, this cell is designated as constructed cell; b)Subjecting the constructed cell to adaptive evolution until a cell that converts arabinose is obtained, c)Optionally, subjecting the first arabinose converting cell to adaptive evolution to improve the arabinose conversion; the cell produced in step b) or c) is designated as first arabinose converting cell; d)Analysing the full genome or part of the genome of the first arabinose converting cell and that of the constructed cell; e)Identifying single nucleotide polymorphisms (SNP's) in the first arabinose converting cell; and f)Using the information of the SNP's in rational design of a cell capable of converting arabinose; g)Construction of the cell capable of converting arabinose designed in step f).

ENZYME PREPARATIONS YIELDING A CLEAN TASTE

The present invention describes an intracellular produced lactase, which comprises less than 40 units arylsulfatase activity per NLU of lactase activity. The invention also provides a process comprising treating a substrate with an enzyme preparation, wherein the enzyme preparation is substantially free from arylsulfatase.

UTROPHIN GENE PROMOTER

Mouse and human utrophin gene promoters are provided. The promoters or fragments and derivatives may be used to control transcription of heterologous sequences, including coding sequences of reporter genes. Expression systems such as host cells containing nucleic acid constructs which comprise a promoter as provided operably linked to a heterologous sequence may be used to screen substances for ability to modulate activity of the utrophin promoter. Substances with such ability may be manufactured and/or used in the preparation of compositions such as medicaments. Up-regulation of utrophin expression may compensate for dystrophin loss in muscular dystrophy patients.

GLYCOSIDASE ENZYMES

A thermostable glycosidase enzymes derived from various thermococcus, staphylothermus and pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.

CELL FOR FERMENTATION MIXTURE OF SUGARS

GENE CODING FOR BETA AGARASE AGAB OF CYTOPHAGA DROBACHIENSIS STOCK DSIJET ITS USE FOR the PRODUCTION Of ENZYMES OF BIOLOGICAL BREAKDOWN OF AGARS

GENE INSULATES CODING FOR THE LAMBDA-CARRAGHENASE AND THE RECOMBINING LAMBDA-CARRAGHENASE OBTAINED USING THIS GENE

Sialylated glycoprotein compositions and uses thereof

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

Polypeptides of Strain Bacillus SP. P203

A new strain Bacillus sp. P203 ( Bacillus plakortiensis ) is disclosed. Isolated mature functional polypeptide which is obtainable from the bacterium strain Bacillus sp. P203 deposited under accession number DSM 17419 are disclosed.

Cellulose binding fusion proteins having a substrate binding region of cellulase

A fusion protein is prepared containing a polypeptide such as an enzyme and an amino acid sequence having a substrate binding region of a polysaccharidase such as cellulase that has essentially no polysaccharidase activity. By contacting the fusion protein with an affinity matrix containing a substrate such as cellulose for the cellulase substrate binding region, the substrate binding region binds to the affinity matrix to immobilize the polypeptide. The polypeptide can be purified by separating the fusion protein or polypeptide from the affinity matrix. The polypeptide can be separated by cleaving the protein with a Cellulomonas fimi protease.

Cloned streptomyces beta-galactosidase gene

A DNA fragment from Streptomyces sp. which contains a gene which can code for an excretable protein is isolated, inserted into a plasmid vector and used to transform other Streptomycetes.

ИДЕНТИФИКАЦИЯ ВАРИАНТА ДНК, СВЯЗАННОГО С ГИПОЛАКТАЗИЕЙ ВЗРОСЛОГО ТИПА

FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and the DNA version related to adult hypolactasia. The substance of invention includes a nucleic acid molecule containing the 5'-end part of the intestinal digestive lactase-phlorizin hydrolase (LPH) gene which participates or serves as an indicator of adult hypolactasia. The said nucleic acid molecule is selected from a group consisting of: (a) nucleic acid molecules having the SEQ ID N0:1 sequence or containing it, where the SEQ ID NO:1 sequence and (b) nucleic acid molecules having the SEQ ID NO:2 sequence or containing it, (c) nucleic acid molecules consisting of at least 20 nucleotides whose complementary strand is hybridised in strict conditions with the nucleic acid molecule at point (a) or (b), where the said polynucleotide/or nucleic acid molecule contains a cytosine residue in a position corresponding to position -13910 in the 5'-direction from the LPH gene; and (d) nucleic acid molecules consisting of at least 20 nucleotides whose complementary strand is hybridised in strict conditions with the nucleic acid molecule at point (a) or (b), where the said polynucleotide/nucleic acid molecule contains a guanine residue in a position corresponding to position -22018 in the 5'-direction from the LPH gene. ^ EFFECT: design of a method of testing presence or predisposition to adult hypolactasia, which is based on SNP analysis, contained in the said nucleic acid molecule. ^ 65 cl, 7 ex, 8 tbl, 9 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 391 404 (13) C2 (51) МПК C12N C12N C12N A61K C12N C12Q A61P ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ 15/09 (2006.01) 9/24 (2006.01) 9/38 (2006.01) 31/7088 (2006.01) 15/55 (2006.01) 1/68 (2006.01) 43/00 (2006.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ (24) Дата начала отсчета срока действия патента: 09.08.2002 (30) Конвенционный приоритет: 10.08.2001 EP 01119377.8 14.08.2001 EP 01119528.6 31.08.2001 US 60/315 ...

КОМПОЗИЦИИ НА ОСНОВЕ СИАЛИРОВАННЫХ ГЛИКОПРОТЕИНОВ И ИХ ПРИМЕНЕНИЕ

FIELD: medicine. SUBSTANCE: disclosed is a composition for treating a lysosomal storage disease, comprising a recombinant glycoprotein, which is human β-glucuronidase and having a degree of sialylation of about 1.1 mol/mol. EFFECT: invention provides high content of sialic acid in the glycoprotein for pharmacological application. 9 cl, 7 dwg, 6 tbl, 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 689 119 C2 (51) МПК A61K 38/47 (2006.01) A61P 3/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 38/47 (2019.02); A61P 3/00 (2019.02); C12N 15/67 (2019.02) (21)(22) Заявка: 2016138790, 05.03.2015 (24) Дата начала отсчета срока действия патента: Дата регистрации: 24.05.2019 05.03.2014 US 61/948,421; 10.02.2015 US 62/114,313 (43) Дата публикации заявки: 09.04.2018 Бюл. № 10 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 05.10.2016 (86) Заявка PCT: US 2015/018859 (05.03.2015) (87) Публикация заявки PCT: R U 2 6 8 9 1 1 9 WO 2015/134696 (11.09.2015) Адрес для переписки: 123242, Москва, пл. Кудринская, д. 1, а/я 35, "Михайлюк, Сороколат и партнеры патентные поверенные" (54) КОМПОЗИЦИИ НА ОСНОВЕ СИАЛИРОВАННЫХ ГЛИКОПРОТЕИНОВ И ИХ ПРИМЕНЕНИЕ (57) Реферат: Изобретение относится к области медицины. степень сиалирования примерно 1,1 моль/моль. Предложена композиция для лечения лизосомной Изобретение обеспечивает увеличение болезни накопления, содержащая содержания сиаловой кислоты в гликопротеине, рекомбинантный гликопротеин, представляющий предназначенном для фармакологического собой β-глюкуронидазу человека и имеющий применения. 8 з.п. ф-лы, 7 ил., 6 табл., 3 пр. (56) (продолжение): Apr; 13(4): 305-13. EA 17622 B1, 30.01.2013. Стр.: 1 C 2 blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA. 2005 Oct 11; 102(41): 14777-82. LEE K. et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid ...

β-ГАЛАКТОЗИДАЗА С ТРАНСГАЛАКТОЗИЛИРУЮЩЕЙ АКТИВНОСТЬЮ

... 1. Последовательность ДНК ! a) кодирующая белок с аминокислотной последовательностью, представленной в SEQ ID NO:2, или ! b) гибридизирующаяся в жестких условиях с последовательностью по п. a), или ! c) являющаяся вырожденной последовательностью, полученной из последовательностей по п. a) или b). ! 2. Последовательность ДНК по п.1, представляющая собой последовательность, представленную в SEQ ID NO:1, или ее фрагмент. ! 3. Последовательность ДНК по п.1 или 2, при этом вышеупомянутая последовательность содержит замены, вставки или удаления нуклеотидов, приводящие к менее чем 60%, предпочтительно к менее чем 45%, и наиболее предпочтительно к менее чем 25% замен в аминокислотной последовательности, представленной в SEQ ID NO:2, или ее фрагмент. ! 4. Последовательность ДНК по п.1 или 2, при этом вышеупомянутая последовательность содержит замены нуклеотидов, приводящие к консервативным аминокислотным заменам. ! 5. Фермент, кодируемый любой из последовательностей ДНК по пп.1-4. ! 6. Фермент, ...

Galactosidase with alph-galactosyltransferase activity

The present invention concerns a b -galactosidase with transgalactosylating activity isolated from Bifidobacterium bifidum. The b -galactosidase is capable of converting lactose to a mixture of oligosaccharides which are b -linked and unexpectedly produces the a -linked disaccharide galactobiose. The mixture may be incorporated into numerous food products or animal feeds for improving gut health by promoting the growth of bifidobacteria in the gut, and repressing the growth of the pathogenic microflora.

Product and Process

METHOD OF PREPARATION OF CLONING VECTOR

Product and process

ARTIFICIAL PROMOTER TO PROTEINS EXPRESSION IN YEAST.

GLYCOSIDASE ENZYMES

POLYPEPTIDE OF MASTER BACTERIA FR P203

PROCEDURE FOR THE PRODUCTION OR FOR THE BIOLOGICAL CONVERSION OF STOFFWECHSELPRODUKTEN OF MEANS OF VEGETABLE CELLS TO VITRO.

SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

ENZYME PREPARATIONS YIELDING A CLEAN TASTE

The present invention describes a intracellular produced lactase, which comprises less than 40 units arylsulfatase activity per NLU of lactase activity. The invention also provides a process comprising treating a substrate with an enzyme preparation, wherein the enzyme preparation is substantially free from arylsulfatase.

HUMANIZED TTC AND METHODS OF USE THEREOF

Compositions and methods for treating neurological diseases and disorders disclosed.

BETA-GALACTOSIDASE WITH TRANSGALACTOSYLATING ACTIVITY

ARTIFICIAL PROMOTER FOR THE EXPRESSION OF PROTEINS IN YEAST

Beta-agarase with homogeneous degradation products and application thereof

PORPHYRANASES AND THEIR USE TO HYDROLIZE POLYSACCHARIDES

PROCESS OF PRODUCTION OR BIOTRANSFORMATION OF METABOLITES BY VEGETABLE CELLS IN VITRO

PROCEDE DE PRODUCTION OU DE BIOTRANSFORMATION DE METABOLITES PAR DES CELLULES VEGETALES IN VITRO PROCEDE CARACTERISE PAR LE FAIT QUE LES CELLULES SONT CULTIVEES EN MILIEU LIQUIDE NON AGITE EN L'ABSENCE DE TOUT SUPPORT ARTIFICIEL D'INCLUSION OU DE FIXATION DE CES CELLULES. PROCESS FOR THE PRODUCTION OR BIOTRANSFORMATION OF METABOLITES BY PLANT CELLS IN VITRO

galactosidade com atividade alfa-galactosiltransferase

ISOLATED GENE CODING FOR λ-CARRAGEENASE AND RECOMBINANT λ-CARRAGEENASE OBTAINED WITH SAID GENE

The invention relates to a gene coding for a polypeptide with an λ-carrageenase activity in other words an enzyme for degradation of carrageenans. The invention further relates to a method for production of said polypeptide in recombinant form by use of genetic techniques and said gene and also the use of said recombinant polypeptide for the degradation of polysaccharides of the carrageenan type to give oligosaccharide fractions.

Method to provide for production of hair coloring pigments in hair follicles

The present invention provides a method to specifically target hair follicles with formulations which effect the production of hair coloring pigments in the follicle. Liposomal formulations for this purpose are disclosed.

NOVEL DNA FRAGMENT, RECOMBINANT VECTOR CONTAINING THE SAME, TRANSFORMANT TRANSFORMED THEREWITH AND UTILIZATION OF THE SAME

METHOD FOR PREPARING BETA-GALACTOSIDASE AND APPLICATION THEREOF

The present disclosure belongs to the technical field of biochemical engineering, and relates to a preparation method of β-galactosidase. The preparation method includes the following steps: step 1, seeding Bacillus circulans into a Luria-Bertani (LB) medium for culture and activation and then into a seed tank for culture to obtain a seed culture broth; step 2, introducing the seed culture broth into a fermentor containing a fermentation medium for fermentation to obtain a fermentation broth of B. circulans; and step 3, filtering or centrifuging the fermentation broth of B. circulans to remove cells to obtain a β-galactosidase liquid; the fermentation medium includes lactose, galactose, phytone, corn meal, yeast extract, a phosphate salt, a carbonate salt, and water. According to the method, fermentation time is short, production period is shortened, and specific activity of the resulting enzyme liquid is high. The present disclosure further provides a preparation method of an immobilized ...

Novel DNA fragment and recombinant vector containing the same, transformant transformed with them, and use thereof

БЕТА-ГАЛАКТОЗИДАЗА С ТРАНСГАЛАКТОЗИЛИРУЮЩЕЙ АКТИВНОСТЬЮ

Изобретение относится к области биохимии. Представлена молекула ДНК, выделенная из Bifidobacterium bifidum, с последовательностью, приведенной в описании, и ее вырожденная производная, кодирующие β-галактозидазу. Также представлен β-галактозидазный фермент, имеющий последовательность, приведенную в описании. Описаны экспрессионный вектор, содержащий указанную ДНК, и бактериальная клетка-хозяин, содержащая данный вектор. Предложено применение фермента или клетки-хозяина для получения смеси олигосахаридов, которые могут быть использованы для приготовления пищевых продуктов, кормов для животных и медикаментов. Описан способ продуцирования фермента, включающий культивирование указанной клетки-хозяина в подходящей культуральной среде в условиях, допускающих экспрессию указанного фермента и выделение полученного фермента из культуры. Изобретение позволяет трансформировать лактозу в смесь олигосахаридов. 9 н. и 3 з.п. ф-лы, 4 ил., 3 табл.

СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОЙ В-1,4-ГАЛАКТОЗИДАЗЫ BGAA ИЗ STREPTOCOCCUS PNEUMONIAE

Изобретение относится к области биотехнологии и решает задачу получения в промышленных объемах высокоочищенной ферментативно активной рекомбинантной β-1,4-галактозидазы BgaA, пригодной для использования на стадии ремоделирования для получения терапевтически функциональных препаратов гликопротеинов с заданными свойствами, для разработки инструментов для высокочувствительного анализа гликановых цепей гликопротеинов тканей растений, животных и микроорганизмов. Способ предусматривает применение металлохелатной, псевдоаффинной, гидрофобной, анионобменной, концентрирующей хроматографии с последующей полирующей гель-фильтрацией, при этом белок из растворимой фракции клеточного лизата очищают с помощью двух стадий хроматографии на одном и том же Niметаллохелатном сорбенте в различных условиях элюции и псевдоаффинной хроматографией в режиме проскока на Blue Sepharose. Применение вышеуказанных трех стадий помогает максимально очистить препарат от мажорных контаминирующих примесей. 9 з.п. ф-лы, 8 ...

ГАЛАКТОЗИДАЗА С АКТИВНОСТЬЮ АЛЬФА-ГАЛАКТОЗИЛТРАНСФЕРАЗЫ

1. Последовательность ДНК, которая ! а) кодирует белок с аминокислотной последовательностью, данной в SEQ ID NO: 2, или ! b) гибридизуется в жестких условиях гибридизации с последовательностью а) или ! c) является вырожденным производным последовательности a) или b). ! 2. Последовательность ДНК по п.1, которая дана в SEQ ID NO: 1 или в ее фрагменте. ! 3. Последовательность ДНК по п.1 или п. 2, которая содержит несколько замен, вставок или делеций, которые в результате приводят к менее 60%, предпочтительно, к менее 45%, более предпочтительно, к менее 25% изменений в аминокислотной последовательности, соответствующей SEQ ID NO: 2 или ее фрагменту. ! 4. Последовательность ДНК по п.1 или п.2, в которых указанная последовательность включает нуклеотидные замены, которые в результате приводят к консервативным заменам аминокислот. ! 5. Фермент, кодируемый последовательностью ДНК по любому из пп.1-4. ! 6. Фермент, содержащий аминокислотную последовательность, соответствующую SEQ ID NO: 2 или ее фрагменту. ! 7. β-галоктозидаза с последовательностью, определенной в SEQ ID NO: 2. ! 8. Рекомбинантный вектор, содержащий последовательность ДНК по любому из пп.1-4. ! 9. Вектор по п.8, в котором указанный вектор является вектором экспрессии. ! 10. Клетка-хозяин, содержащая последовательность ДНК по любому из пп.1-4. ! 11. Клетка-хозяин, содержащая вектор по п.8 или п.9. ! 12. Клетка-хозяин по п.10 или п.11, в которых указанная клетка является бактериальной клеткой, дрожжевой клеткой или грибковой клеткой. ! 13. Клетка-хозяин по п.12, в котором указанная клетка выбрана из группы, состоящей из Bifidobacterium, Lactococcus, Lactobacillus, Escherichia, Bacillus и Aspergillus. ! 14. Клетка-хозяин по п. 13, в котором клетка выбрана из группы, состоящей из РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2008 135 344 (13) A (51) МПК C12N 9/38 (2006.01) C12N 15/55 (2006.01) C12N 15/11 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21 ...

BETA-GALACTOSIDASE MIT TRANSGALACTOSYLIERUNGSAKTIVITÄT

Beta-galactosidase with transgalactosylating activity

ISOLATION OF FERMENTATION PRODUCTS

AUXILIARY TEST PROCEDURE OF PROTEINS BINDING ENZYMES.

GLYKOSIDASEENZYME

An enzyme with galactanase activity

Method for preserving polypeptides using a sugar and polyethyleneimine

IDENTIFICATION OF A DNA VARIANT ASSOCIATED WITH ADULT TYPE HYPOLACTASIA

The present invention relates to a nucleic acid molecule comprising a 5' portion of an intestinal lactase-phlorizine hydrolase (LPH) gene contributing to or indicative of the adult-type hypolactasia wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, the sequence of SEQ ID NO:1 is also depicted in the Fig. 4 and comprised in the sequence as depicted in the Fig. 8; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 2, the sequence of SEQ ID NO:2 is also depicted in Fig.5 and comprised in the sequence as depicted in the Fig. 9; (c) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -13910 5' from the LPH gene a cytosine residue; and (d) a nucleic acid molecule of at least 20 nucleotides the complementary strand of which hybridizes under stringent conditions to the nucleic acid molecule of (a) or (b), wherein said polynucleotide/nucleic acid molecule has at a position corresponding to position -22018 5' from the LPH gene a guanine residue. The present invention further relates to methods for testing for the presence of or predisposition to adult-type hypolactasia that are based on the analysis of an SNP contained in the above recited nucleic acid molecule. Additionally, the present invention relates to diagnostic composition and kit useful in the detection of the presence of or predisposition to adult-type hypolactasia.

LIQUID LACTASE COMPOSITIONS

The invention provides an aqueous liquid lactase formulation comprising lactase and further comprising sodium, calcium or potassium-L-lactate or a combination thereof and optionally a sugar, and/or optionally comprising sodium or potassium chloride or a combination thereof, preferably wherein the concentration of each of the components is such that the water activity Aw is at most 0.82. The formulation is particularly suitable when using invertase-free lactase, allowing the use of sucrose as stabilizer. The invention also provides a process to produce the liquid lactase formulation of the invention, an infant formula (e.g. as powder of granulate) comprising the liquid lactase formulation of the invention, a method to produce said infant formula, and the use of the formulation in the production of infant formula.

A METHOD FOR TREATING BIOFILM AND OTHER SLIME PRODUCTS WITH ENDO-BETA-1,2-GALACTANASE

The invention describes a method for degrading polysaccharides by using an enzyme preparation comprising endo-.beta.-1,2-galactanase activity. In the process industry and in the paper machine environment in particular, microbe s form biofilms on surfaces, consisting of microbes, fibres, and polysaccharid e that protects the microbe cells, increases the viscosity of the biofilm, and protects the biofilm against drying. By treating biofilms and other slime deposits in the process industry with the enzyme preparation according to th e invention, the problems caused by biofilms to the process industry can be reduced. Endo-.beta.-1,2-galactanase can also be used in the preparation of various mono- or oligosaccharides.

GALACTO-OLIGOSACCHARIDE-CONTAINING COMPOSITION AND A METHOD OF PRODUCING IT

The present invention relates to a method of producing compositions containing galacto-oligosaccharides as well as to galacto-oligosaccharide-containing compositions as such.

CELL SUITABLE FOR FERMENTATION OF A MIXED SUGAR COMPOSITION

The present invention relates to a cell suitable for production of one or more fermentation product from a sugar composition comprising glucose, galactose, arabinose and xylose, wherein the cell comprises two to fifteen copies of one or more xylose isomerase gene or two to fifteen copies of one or more xylose reductase and xylitol 10 dehydrogenase, and two to ten copies of araA, araB and araD, genes, wherein these genes are integrated into the cell genome.

ARTIFICIAL PROMOTER FOR THE EXPRESSION OF PROTEINS IN YEAST

The invention relates to an artificial promoter for the expression of proteins in yeast, which comprises: - a sub-sequence upstream from the TATA component of the sequence of the promoter of the GAL7 gene of Saccharomyces cerevisiae, which comprises the upstream activation sequences UAS1 and UAS2; and - a sub-sequence of the sequence of an ADH2 promoter comprising the TATA component and the transcription initiation region. Application: Preparation of proteins, especially urate oxidase.

METHOD FOR DELIVERING BENEFICIAL COMPOSITIONS TO HAIR FOLLICLES

The present invention describes a method for targeted and specific delivery of beneficial compounds including hair dyes, melanin, proteins, and nucleic acids for gene therapy, to hair follicle cells using l iposomes encapsulating the beneficial compound. Particul arly preferred methods describe delivery of hair dyes, melanin or tyrosinase to t he hair follicle for the purpose of improving hair color or condition, either by encapsulating the compounds in liposomes, or by encapsu lating a nucleic acid capable of expressing the protein in liposomes. Also described are liposome compositions for practising the metho ds.

solução de lactase e produto lácteo usando a mesma

FRAGMENT COMPLEMENTATION BASED ASSAYS

The present disclosure provides, among other things, methods and compositions for detecting and/or quantifying analytes using fragment complementation technologies. In accordance with various embodiments of the present disclosure, a kit can include a) a capture probe immobilized on a surface, wherein the capture probe can associate with an analyte in a sample, thereby forming at least one captured analyte; b) a detection element including a target interacting probe associated with a first subunit of a detectable entity, wherein the target interacting probe can associate with the captured analyte so that a first complex is formed; and c) a second subunit that can complement the first subunit and generate a detectable entity, wherein the presence and/or amount of the analyte is indicated by detecting level or activity of the detectable entity.

NUCLEIC ACIDS OF ASPERGILLUS FUMIGATUS ENCODING INDUSTRIAL ENZYMES AND METHODS OF USE

The present invention provides nucleotide sequences of Aspergillus fumigatus that encode proteins which exhibit enzyme activities. Vectors, expression constructs, and host cells comprising the nucleotide sequences of the enzyme genes are also provided. The invention further provides methods for producing the enzymes, and methods for modifying the enzymes in order to improve their desirable characteristics. The activities displayed by the enzymes of the invention include those of a tannase, cellulase, glucose oxidase, glucoamylase, phytase, β-glactosidases, invertase, lipase, α-amylase, laccase, polygalacturonase or xylanase. The enzymes of the invention can be used in a variety of industrial processes. Enzymatically active compositions in various forms as well as antibodies to the enzymes and fragments thereof, are also provided.

Glycosidase enzymes

A thermostable glycosidase enzymes derived from various thermococcus, staphylothermus and pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.

Enzyme preparations yielding a clean taste

The present invention describes an intracellular produced lactase which comprises less than 40 units arylsulfatase activity per NLU of lactase activity. The invention also provides a process comprising treating a substrate with an enzyme preparation, wherein the enzyme preparation is substantially free from arylsulfatase.

ГАЛАКТОЗИДАЗА С АКТИВНОСТЬЮ АЛЬФА-ГАЛАКТОЗИЛТРАНСФЕРАЗЫ

FIELD: biochemistry. SUBSTANCE: present invention relates to a β-galactosidase with transgalactosylating activity with the sequence provided in the description and the relative coding DNC. A recombinant vector incorporating the DNA sequence and a host cell comprising the DNA sequence or the vector are also disclosed. The enzyme with transgalactosylating activity is proposed for producing a mixture of oligosaccharides comprising disaccharides, trisaccharides, tetrasaccharides and pentasacchrides. Method for producing a mixture of oligosaccharides including bringing the enzyme or the host-cell in contact with the lactose-containing material. EFFECT: invention enables the production of a mixture of oligosaccharides by enzymic lactose transformation. 17 cl, 4 dwg, 3 tbl, 2 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 441 913 (13) C2 (51) МПК C12N 9/38 (2006.01) C12N 15/55 (2006.01) C12N 15/11 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2008135344/10, 23.01.2007 (24) Дата начала отсчета срока действия патента: 23.01.2007 (73) Патентообладатель(и): КЛАСАДО ИНК. (PA) (43) Дата публикации заявки: 10.03.2010 Бюл. № 7 2 4 4 1 9 1 3 (45) Опубликовано: 10.02.2012 Бюл. № 4 (56) Список документов, цитированных в отчете о поиске: WO 2005003329 A1, 13.01.2005. RU 93045473 A, 20.04.1996. EP 0764720 A1, 26.03.1997. WO 2004080200 A1, 23.09.2004. 2 4 4 1 9 1 3 R U (86) Заявка PCT: GB 2007/000178 (23.01.2007) C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 01.09.2008 (87) Публикация заявки РСТ: WO 2007/088324 (09.08.2007) Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр.3, ООО "Юридическая фирма Городисский и Партнеры", А.В.Мицу (54) ГАЛАКТОЗИДАЗА С АКТИВНОСТЬЮ АЛЬФА-ГАЛАКТОЗИЛТРАНСФЕРАЗЫ (57) Реферат: Настоящее изобретение относится к биохимии. Представлена β-галактозидаза, имеющая трансгалактозилирующую активность, с последовательностью, представленной в описании, и кодирующая ее ДНК. ...

ZELLULOSEBINDENDE FUSIONSPROTEINE

Method for preserving polypeptides using a sugar and polyethyleneimine

A method for preserving a polypeptide comprises (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide wherein the concentration of polyethyleneimine is 25 M or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M; and (ii) drying the solution to form an amorphous solid matrix comprising said polypeptide.

Galactosidase with alph-galactosyltransferase activity

Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures

A method for treating biofilm and other slime products with endo-beta-1,2-galactanase

PRODUCTION OF ETHANOL AND EXOGENOUS PROTEN BY YEAST

Compositions and methods for treating Parkinson's disease

Described herein are methods for treating a subject having or at risk of developing Parkinson's disease, by administering pluripotent cells that express glucocerebrosidase (GBA) or pluripotent cells that express GBA and one or more M2-promoting agents to the subject. Also disclosed are compositions comprising pluripotent cells expressing GBA, such as pluripotent cells expressing GBA and one or more M2-promoting agents.

SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

METHOD FOR ASSAYING ARYLSULFATASE ACTIVITY

Provided is a method for determining activity of arylsulfatase in an aqueous system, which comprises a step in which arylsulfatase is subjected to reaction with a substrate, from which fluorophore or chromophore is liberated by suffering an action of the arylsulfatase, in an aqueous reaction system having high ionic strength. Also, provided are a lactase preparation having a lactase activity of 4,000 NLU/g or more according to the FCC IV method and having an arylsulfatase activity of 0.1% or less of the lactase activity as the basis, in which the arylsulfatase activity has been determined by the method for determining activity of arylsulfatase in an aqueous system according to the fluorescence method of the present invention; a method for producing this preparation; and a dairy product which comprises using this preparation. 1. A method for determining activity of arylsulfatase in an aqueous system characterized in that arylsulfatase is subjected to reaction with a substrate , from which fluorophore or chromophore is liberated by suffering an action of the arylsulfatase , in an aqueous reaction system having high ionic strength.2. The method for determining activity of arylsulfatase in an aqueous system according to claim 1 , wherein the means for reaction in an aqueous reaction system having high ionic strength is one in which the enzyme is subjected to reaction with a substrate in an aqueous reaction system to which an inorganic salt has been added claim 1 , and/or claim 1 , another one in which the enzyme is subjected to reaction with a substrate in a buffer that does not denature the enzyme protein.3. The method for determining activity of arylsulfatase in an aqueous system according to claim 2 , wherein the concentration of the inorganic salt in the aqueous reaction system is 50 to 500 mM claim 2 , and/or claim 2 , the concentration of the buffer is 50 to 200 mM.4. The method for determining activity of arylsulfatase in an aqueous system according to claim 2 , ...

COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE

Described herein are methods for treating a subject having or at risk of developing Parkinson's disease, by administering pluripotent cells that express glucocerebrosidase (GBA) or pluripotent cells that express GBA and one or more M2-promoting agents to the subject. Also disclosed are compositions comprising pluripotent cells expressing GBA, such as pluripotent cells expressing GBA and one or more M2-promoting agents. 1. A method of treating Parkinson's disease in a subject , the method comprising administering to the subject a composition comprising a population of pluripotent cells that express a transgene encoding glucocerebrosidase (GBA).2. The method of claim 1 , wherein the GBA is full-length GBA.3. The method of claim 1 , wherein the GBA is a catalytic domain of GBA.4. The method of any one of - claim 1 , wherein the GBA has an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO. 1.5. The method of claim 4 , wherein the GBA has an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO. 1.6. The method of claim 5 , wherein the GBA has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1.7. The method of claim 6 , wherein the GBA has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 1.8. The method of any one of - claim 6 , wherein the GBA has an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO. 5.9. The method of claim 8 , wherein the GBA has an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO. 5.10. The method of claim 9 , wherein the GBA has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO. 5.11. The method of claim 10 , wherein the GBA has the amino acid sequence of SEQ ID NO. 5.12. The method of any one of - claim 10 , wherein the transgene encoding GBA has a nucleic ...

AGARASE-3,6-ANHYDRO-L-GALACTOSIDASE-ARABINOSE ISOMERASE ENZYME COMPLEX AND METHOD FOR PRODUCTION OF TAGATOSE FROM AGAR USING THE SAME

The present disclosure relates to an enzyme complex of arabinose isomerase, agarase and 3,6-anhydro galactosidase and a method for producing tagatose by degrading agar using the same. By using the enzyme complex according to the present disclosure, agar obtained from marine biomass can be degraded effectively and useful physiologically active substances such as tagatose can be obtained effectively therefrom. 1. An agarase complex wherein:a fusion protein 1 in which a monosaccharide convertase and a dockerin module are bound;a fusion protein 2 in which agarase and a dockerin module are bound; anda fusion protein 3 in which 3,6-anhydro-L-galactosidase and a dockerin module are bound;are linked via dockerin-cohesin binding by a mini scaffold protein comprising a cohesin module.2Lactobacillus.. The enzyme complex according to claim 1 , wherein the monosaccharide convertase is arabinose isomerase derived from3. The enzyme complex according to claim 2 , wherein the arabinose isomerase comprises amino acid sequence of SEQ ID NO 1.4. The enzyme complex according to claim 1 , wherein the dockerin is derived from cellulase.5. The enzyme complex according to claim 4 , wherein the dockerin is encoded nucleotide sequence of SEQ ID NO 35.6. The enzyme complex according to claim 4 , wherein the cellulase is selected from a group consisting of endo-β-1 claim 4 ,4-glucanase B claim 4 , endo-β-1 claim 4 ,4-xylanase B and exo-glucanase S.7Pseudomonas, SaccharophagusAleromonas.. The enzyme complex according to claim 1 , wherein the agarase is derived from one selected from a group consisting of and8. The enzyme complex according to claim 7 , wherein the agarase is β-agarase.9. The enzyme complex according to claim 8 , wherein the β-agarase is encoded nucleotide sequence of SEQ ID NO 26.10Zobellia.. The enzyme complex according to claim 1 , wherein the 3 claim 1 ,6-anhydro-L-galactosidase is derived from11. The enzyme complex according to claim 10 , wherein the 3 claim 10 ,6-anhydro-L- ...

ENZYME COMPLEX COMPRISING BETA-AGARASE, KAPPA-CARRAGEENASE AND ANHYDRO-GALACTOSIDASE, AND USE THEREOF

The present invention relates to an enzyme complex which the following (i) to (iv) are combined: (i) chimeric beta-agarase formed by a fusion of beta-agarase and the dockerin module of endo-β-1,4-glucanase-B; (ii) chimeric kappa-carrageenase formed by a fusion of kappa-carrageenase and the dockerin module of endo-β-1,4-glucanase-B; (iii) chimeric anhydro-galactosidase formed by a fusion of anhydro-galactosidase and the dockerin module of endo-β-1,4-glucanase-B; and (iv) mini cellulose-binding protein A, and to a method of degrading red algal biomass using the same. According to the present invention, an enzymatic degradation process is applied for the production of agar degradation products, deviating from conventional methods that relied on physical and chemical pretreatment processes. Thus, the present invention will greatly contribute to efficiently converting marine algae into valuable products by use of a convenient, cost-effective, highly efficient and environmentally friendly degradation system while controlling the products. 1. An enzyme complex which the following (i) to (iv) are combined:(i) chimeric beta-agarase formed by a fusion of beta-agarase and the dockerin module of endo-β-1,4-glucanase-B;(ii) chimeric kappa-carrageenase formed by a fusion of kappa-carrageenase and the dockerin module of endo-β-1,4-glucanase-B;(iii) chimeric anhydro-galactosidase formed by a fusion of anhydro-galactosidase and the dockerin module of endo-β-1,4-glucanase-B; and(iv) mini cellulose-binding protein A.2. The enzyme complex of claim 1 , wherein the beta-agarase has the amino acid sequence of SEQ ID NO: 1.3. The enzyme complex of claim 1 , wherein the kappa-carrageenase has the amino acid sequence of SEQ ID NO: 2.4. The enzyme complex of claim 1 , wherein the anhydro-galactosidase has the amino acid sequence of SEQ ID NO: 3.5. The enzyme complex of claim 1 , wherein the endo-β-1 claim 1 ,4-glucanase-B has the amino acid sequence of SEQ ID NO: 4.6. The enzyme complex of ...

Heat-resistant agarase and monosaccharide production method using same

The present invention relates to a heat-resistant agarase and a monosaccharide production method using same. More particularly, in the present invention, a heat-resistant agarase may be used to produce galactose and 3,6-anhydro-L-galactose at high yield by efficiently breaking down agarose or agar without a chemical pretreatment, a neutralization process, or an agarotriose hydrolase treatment process.

METHOD FOR ASSAYING ARYLSULFATASE ACTIVITY

A lactase preparation includes lactase and has a lactase activity of 4,000 NLU/g or more according to the FCC IV method, wherein the lactase originates from a lactase gene of yeast, and wherein the lactase preparation has an arylsulfatase activity of 0.1% or less based on the lactase activity, in which the arylsulfatase activity (unit: U/g) is determined and calculated. 115-. (canceled)16. A lactase preparation comprising lactase and having a lactase activity of 4 ,000 NLU/g or more according to the FCC IV method , wherein the lactase originates from a lactase gene of yeast , and wherein the lactase preparation has an arylsulfatase activity of 0.1% or less based on the lactase activity , in which the arylsulfatase activity (unit: U/g) is determined and calculated by a method comprising:(a) obtaining a sample by diluting the lactase preparation as a specimen in which the existence of the arylsulfatase is predicted with 100 mM potassium phosphate buffer (pH6.5) comprising 0.5M potassium chloride,(b) preparing an aqueous solution comprising potassium 4-methylumbelliferone sulfate in a concentration of 2 mM,(c) mixing the sample and the aqueous potassium 4-methylumbelliferone sulfate solution with each other at a ratio of 1:1 (volume basis) to react them at 37 degrees Celsius for 3 hours,(d) adding to the reacted solution, 0.1N aqueous sodium hydroxide solution having the same amount (volume basis) as that of the reacted solution to stop the reaction, thus obtaining a sample for determination,(e) determining fluorescence intensity at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm,(f) preparing a plurality of 4-methylumbelliferone solutions with different 4-methylumbelliferone concentrations in 100 mM potassium phosphate buffer (pH6.5) comprising 0.5M potassium chloride, adding 0.1N aqueous sodium hydroxide solution to each of the plurality of 4-methylumbelliferone solutions in a similar way as in (d), and determining fluorescence intensities ...

METHOD FOR ASSAYING ARYLSULFATASE ACTIVITY

Provided is a method for determining activity of arylsulfatase in an aqueous system, which comprises a step in which arylsulfatase is subjected to reaction with a substrate, from which fluorophore or chromophore is liberated by suffering an action of the arylsulfatase, in an aqueous reaction system having high ionic strength. Also, provided are a lactase preparation having a lactase activity of 4,000 NLU/g or more according to the FCC IV method and having an arylsulfatase activity of 0.1% or less of the lactase activity as the basis, in which the arylsulfatase activity has been determined by the method for determining activity of arylsulfatase in an aqueous system according to the fluorescence method of the present invention; a method for producing this preparation; and a dairy product which comprises using this preparation. 113.-. (canceled)14. A method for producing a lactase preparation characterized by:culturing a diploid strain of yeast having a lactase gene, in which expression of arylsulfatase protein is restricted, or a gene-recombinant microorganism in which a lactase gene of yeast has been transformed and expression of arylsulfatase protein is restricted;gathering yeast or microorganism cells without destroying their cell walls, gathering culture fluid with yeast or microorganism cells after destruction of their cell walls, or gathering culture fluid without destroying cell walls; andpreparing a lactase preparation by using, as a raw material, the gathered yeast or microorganism cells and/or gathered culture fluid without a step for removing arylsulfatase;wherein the lactase preparation has a lactase activity of 4.000 NLU/a or more according to the FCC IV method; and (1) a specimen in which the existence of the arylsulfatase is predicted is arbitrarily diluted with 100 mM potassium phosphate buffer (pH6.5) comprising 0.5M potassium chloride to obtain a sample,', '(2) an aqueous solution comprising potassium 4-methylumbelliferone sulfate in a concentration ...

Agarase, Composition Containing the Same, and Application thereof

The present invention provides a β-agarase, a composition containing the same and applications thereof. The present β-agarase provides the field a novel alternative and is favorable for the industrial utilities of the hydrolysis products of agarose. Furthermore, the present agarase is particularly modified for heterologous production by prokaryotic expression systems, and thereby is favorable for commercial use. 1. A β-agarase , comprising at least an amino acid sequence as shown in SEQ ID NO: 06; provided that said amino acid sequence of said β-agarase is not SEQ ID NO: 31.2. The β-agarase of claim 1 , having an amino acid sequence as shown in SEQ ID NO: 01.3. The β-agarase of claim 1 , having an amino acid sequence as shown SEQ ID NO: 02.4. The β-agarase of claim 1 , having an amino acid sequence as shown SEQ ID NO: 03.5. The β-agarase of claim 1 , having an amino acid sequence as shown SEQ ID NO: 04.6. The β-agarase of claim 1 , having an amino acid sequence as shown SEQ ID NO: 05.7. The β-agarase of claim 1 , having an amino acid sequence as shown SEQ ID NO: 06.8. A composition for digesting polysaccharide with α-1 claim 1 ,3 and β-1 claim 1 ,4 glycosidic linkage claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '0.1 to 10 U/mL of the agarase of ; and'}1 to 2 mM of a salt;wherein said U/mL and said mM are based on a total volume of said composition.9. The composition of claim 8 , further comprising 50 to 200 mM of a buffer based on a total volume of said composition.10. The composition of ; wherein said salt is KCl claim 8 , ZnSO claim 8 , FeSO claim 8 , BaCl claim 8 , NaCl claim 8 , SrCl claim 8 , CoCl claim 8 , MgSO claim 8 , MnCl claim 8 , CaCl claim 8 , AlCl claim 8 , or a combination thereof.11. The composition of ; wherein said salt is FeSO claim 10 , CoCl claim 10 , MnCl claim 10 , CaCl claim 10 , AlCl claim 10 , or a combination thereof.12. The composition of claim 8 , said polysaccharide with α-1 claim 8 ,3 and β-1 claim 8 ,4 ...

SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders. 127.-. (canceled)28. A method for treating mucopolysaccharidosis type 7 in a subject in need thereof , comprising administering to the subject a composition comprising a recombinant β-glucuronidase , wherein the recombinant β-glucuronidase is administered every other week by continuous intravenous infusion at a dose of 1 mg/kg to 8 mg/kg.29. The method of claim 28 , wherein the subject is a human.30. The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of 2 mg/kg to 6 mg/kg.31. The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of 4 mg/kg.32. The method of claim 28 , wherein the recombinant β-glucuronidase is administered concurrently with or following antihistamine therapy. This application is a Continuation of U.S. patent application Ser. No. 15/607,257, filed May 26, 2017 (now U.S. Pat. No. 9,937,243, issued Apr. 10, 2018), which is a Continuation of U.S. patent application Ser. No. 15/251,701, filed Aug. 30, 2016 (now U.S. Pat. No. 9,687,532, issued Jun. 27, 2017), which is a Continuation of U.S. patent application Ser. No. 14/639,171, filed Mar. 5, 2015 (now U.S. Pat. No. 9,457,067, issued Oct. 4, 2016), which claims priority to U.S. Provisional Application No. 61/948,421, filed Mar. 5, 2014, and U.S. Provisional Application No. 62/114,313, filed Feb. 10, 2015, each of which is herein incorporated by reference in their entireties for all purposes.The present invention relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: ULPI_020_06US_SeqList_ST25.txt, date recorded: Nov. 2, 2018, file size: 6 ...

METHOD FOR PRODUCING LACTASE-CONTAINING COMPOSITION

A method for producing a lactase-containing composition which is purified by selectively removing protease contaminating the lactase using simple and easy means; a lactase-containing composition; and a dairy product containing the lactase-containing composition. 1. A method for producing a lactase-comprising composition having a reduced protease content , the method comprising:dissolving a composition comprising lactase and protease in an aqueous salt solution having an electric conductivity of from 2 to 45 mS/cm to obtain a resultant solution;bringing the resultant solution into contact with an ion exchange resin; andcollecting a fraction which is not adsorbed onto the ion exchange resin.2. The production method according to claim 1 , whereinthe composition comprising lactase and protease is a lactase-comprising composition produced by a microorganism.3. The production method according to claim 1 , whereinthe aqueous salt solution is an aqueous solution of an inorganic acid salt.4. The production method according to claim 1 , whereinthe ion exchange resin is an anion exchange resin.5. The production method according to claim 1 , whereinthe ion exchange resin is an anion exchange resin membrane.6. The production method according to claim 1 , whereinthe lactase-comprising composition having a reduced protease content has a ratio of protease activity to lactase activity of not more than 0.02%.7. A lactase-comprising composition claim 1 , which has a ratio of protease activity to lactase activity of not more than 0.02%.8. A lactase-comprising composition claim 1 , obtained by the method according to claim 1 ,wherein the lactase-comprising composition has a ratio of protease activity to lactase activity of not more than 0.02%.9. The lactase-comprising composition according to claim 7 , whereinfor a processed milk obtained by allowing milk to comprise 0.1 mass % of the lactase-comprising composition and to stand still at 30° C. for 3 months,when the processed milk is ...

Polynucleotide Constructs For In Vitro and In Vivo Expression

The present invention relates to polynucleotide constructs for in vitro and in vivo transcription/translation of genes of interest or variants of a gene of interest as well as microorganism host cells comprising such constructs and methods for producing a polypeptide of interest in such microorganism host cells.

AGARASE, COMPOSITION CONTAINING THE SAME, AND APPLICATION THEREOF

The present invention provides a β-agarase, a composition containing the same and applications thereof. The present β-agarase provides the field a novel alternative and is favorable for the industrial utilities of the hydrolysis products of agarose. Furthermore, the hydrolysis product of agarose by the present β-agarase has high purity of neoagarotetraose therefore the present β-agarase is especially useful for the neoagarotetraose's utilities in the field. 1. A composition for hydrolyzing agarose , comprising:0.1 to 10 U/mL of a β-agarase; and1 to 2 mM of a salt;wherein said β-agarase comprises a sequence as SEQ ID NO 01 or is encoded by a sequence as SEQ ID NO 02;wherein said U/mL and mM are based on a total volume of said composition.2. The composition of claim 1 , further comprising 50 to 200 mM of a buffer based on a total volume of said composition; wherein said buffer is citrate buffer (pH 5 to 6) or phosphate buffer (pH 6 to 7).3. The composition of claim 1 , wherein said salt is CuSO claim 1 , KCl claim 1 , FeSOBaCl claim 1 , NaCl claim 1 , SrCl claim 1 , CoCl claim 1 , MgSO claim 1 , MnCl claim 1 , CaCl claim 1 , AlCl claim 1 , or a combination thereof.4. The composition of claim 1 , wherein said β-agarase is produced by exogenously expressing the nucleotide sequence as SEQ ID NO 02 by a gene expression system.5E. coli. The composition of claim 4 , wherein said gene expression system is an gene expression system.6. The composition of claim 1 , wherein said β-agarase is produced by exogenous expression of an expression vector contained in a gene expression system; wherein said expression vector comprises a nucleotide sequence as SEQ ID NO 02.7. The composition of claim 6 , wherein said expression vector has a nucleotide sequence as SEQ ID NO 05.8. The composition of claim 6 , wherein said exogenous expression is conducted at 15 to 32° C.9. A method for agarose hydrolysis claim 6 , comprising the following steps:(A) providing a sample, which comprises ...

Polypeptides Having Beta-1,3-Galactanase Activity and Polynucleotides Encoding Same

The present invention relates to polypeptides having beta-1,3-galactanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. 1. A polypeptide having beta-1 ,3-galactanase activity , selected from the group consisting of:(a) a polypeptide having at least 65% sequence identity to the mature polypeptide of SEQ ID NO: 2;(b) a polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions with the mature polypeptide coding sequence of SEQ ID NO: 1 or the full-length complement hereof;(c) a polypeptide encoded by a polynucleotide having at least 65% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1;(d) a variant of the mature polypeptide of SEQ ID NO: 2 comprising a substitution, deletion, and/or insertion at one or more positions; and(e) a fragment of the polypeptide of (a), (b), (c), or (d) that has beta-1,3-galactanase activity.2. The polypeptide of claim 1 , which is an isolated polypeptide.3. The polypeptide of claim 1 , having at least 65% sequence identity to the mature polypeptide of SEQ ID NO: 2.4. The polypeptide of claim 1 , which is encoded by a polynucleotide that hybridizes under low stringency conditions claim 1 , low-medium stringency conditions claim 1 , medium stringency conditions claim 1 , medium-high stringency conditions claim 1 , high stringency conditions claim 1 , or very high stringency conditions with the mature polypeptide coding sequence of SEQ ID NO: 1 or the full-length complement hereof.5. The polypeptide of claim 1 , which is encoded by a polynucleotide having at least 65% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1.6. The polypeptide of claim 1 , comprising or consisting of SEQ ID NO: 2 or the mature polypeptide of SEQ ID NO: 2.7. The polypeptide of claim 1 , wherein the mature ...

POLYPEPTIDES HAVING TRANSGALCTOSYLATING ACTIVITY

The present invention relates to polypeptides, specifically polypeptides having transgalactosylating activity and nucleic acids encoding these, and their uses in e.g. dairy product. 1. A polypeptide having transgalactosylating activity selected from the group consisting of:a. a polypeptide comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1, wherein said polypeptide consists of at most 950, 940, 930, 920, 910, 900, or 890 amino acid residues.2. The polypeptide according to comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1 claim 1 , wherein said polypeptide consists of at most 890 amino acid residues.3. (canceled)4. (canceled)5. The polypeptide according to which consists of the amino acid sequence of SEQ ID NO: 1.6. (canceled)7. The polypeptide according to claim 1 , wherein said polypeptide has a ratio of transgalactosylation activity above 100%.8. A nucleic acid capable of encoding a polypeptide according to .9. An expression vector comprising a nucleic acid according to .10. A cell capable of expressing a polypeptide according to .11. A method of expressing a polypeptide claim 10 , the method comprising obtaining a cell according and expressing the polypeptide from the cell claim 10 , and optionally purifying the polypeptide.12. A composition comprising a polypeptide according to claim 1 , preferably a food composition claim 1 , more preferably a dairy product.13. A method for producing a food product by treating a substrate comprising lactose with a polypeptide according to .14. A method for producing a dairy product by treating a milk-based substrate comprising lactose with a polypeptide according to .15. A process for producing galacto-oligosaccharides claim 1 , comprising contacting of a polypeptide of according to with a milk-based solution comprising lactose. The present invention relates to polypeptides, specifically polypeptides having transgalactosylating activity and nucleic ...

ENZYME PREPARATIONS YIELDING A CLEAN TASTE

The present invention describes a intracellular produced lactase, which comprises less than 40 units arylsulfatase activity per NLU of lactase activity. The invention also provides a process comprising treating a substrate with an enzyme preparation, wherein the enzyme preparation is substantially free from arylsulfatase. 1. A lactase which comprises less than 40 units arylsulfatase activity per NLU of lactase activity.2. The lactase according to claim 1 , which comprises less than 10 units arylsulfatase activity per NLU of lactase activity.3. The lactase according to claim 1 , which is an intracellular produced lactase.4. The lactase according to claim 1 , which is a neutral lactase.5K. lactis. The lactase according to claim 4 , which is a lactase.6. The lactase according to claim 1 , which has a pH optimum of between pH=6 and pH=8.7. The lactase according to claim 1 , which has less than 0.5 RFU/min protease activity per NLU of lactase activity.8. A composition comprising the lactase of .9. A dairy product comprising the lactase of .10. A process to produce a dairy product which comprises adding a lactase of to a dairy product which comprises lactose.11. A process to produce a dairy product which is free of off flavours produced by arylsulfatase which comprises using a lactase of .12. A process to purify a lactase-containing enzyme preparation claim 1 , which comprises separation of aryl-sulfatase from lactase using chromatography.13. A process comprising treating a substrate with an enzyme preparation claim 1 , wherein the enzyme preparation is substantially free from arylsulfatase.14. A process for preparing an enzyme preparation claim 1 , said process comprising purifying a crude enzyme preparation which contains an enzyme of interest and arylsulfatase claim 1 , wherein arylsulfatase is separated from the enzyme of interest.15. A process comprising treating a substrate with an enzyme preparation obtained by a process of .16. The process according to claim 15 , ...

EXPANSIN-AGARASE ENZYME COMPLEX AND METHOD FOR DEGRADING AGAR BY USING SAME

The present invention relates to an expansin-agarase enzyme complex and a method of degrading agar by using the same. The use of the enzyme complex according to the present invention can efficiently degrade agar obtained from marine biomass, and thus can efficiently provide not only galactose or glucose necessary for ethanol production, but also useful biologically active substances, such as diose, triose, and oligosaccharides. 1. An expansin-agarase enzyme complex in which a fusion protein of the dockerin module of cellulase and an expansin protein and a fusion protein of the dockerin module of cellulase and agarase are assembled with a cohesin module via dockerin-cohesin interaction.2. The enzyme complex of claim 1 , wherein the dockerin module is derived from endo-beta-1 claim 1 ,4-glucanase-B.3. The enzyme complex of claim 1 , wherein the expansin protein has an amino acid sequence set forth in SEQ ID NO: 1.4. The enzyme complex of claim 1 , wherein the cohesin module is a mini-cellulose-binding protein A (mCbpA).5. The enzyme complex of claim 1 , wherein the agarase is encoded by a nucleotide sequence set forth in SEQ ID NO: 20.6. A method for producing the expansin-agarase enzyme complex of claim 1 , comprising the steps of:(a) preparing a fusion protein of the dockerin module of cellulase and an expansin protein;(b) preparing a fusion protein of the dockerin module of cellulase and agarase; and(c) mixing the fusion protein of the dockerin module of cellulase and the expansin protein and the fusion protein of the dockerin module of cellulase and agarase with the cohesin module, thereby preparing the enzyme complex by dockerin-cohesin interaction.7. A method of degrading agar using the expansin-agarase enzyme complex of .8. The method of claim 7 , wherein the agar is purified agar claim 7 , red algae-derived agar claim 7 , agar present in red algae. The present invention relates to an expansin-agarase enzyme complex and a method of degrading agar using the same ...

COMPOSITIONS COMPRISING BETA-MANNANASE AND METHODS OF USE

The present compositions and methods relate to a beta-mannanase from polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM). 112-. (canceled)13. An enzyme composition comprising a recombinant polypeptide comprising an amino acid sequence that is at least 55% identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:3 , wherein the polypeptide has beta-mannanase activity , and further comprising one or more cellulases.14. The enzyme composition of claim 13 , wherein the one or more cellulases are selected from one or more beta-glucosidases claim 13 , one or more cellobiohydrolases claim 13 , and one or more endoglucanases.15. An enzyme composition comprising a recombinant polypeptide comprising an amino acid sequence that is at least 55% identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:3 claim 13 , wherein the polypeptide has beta-mannanase activity claim 13 , and further comprising one or more other hemicellulases.16. The enzyme composition of claim 15 , wherein the one or more other hemicellulases are selected from one or more other beta-mannanases claim 15 , one or more one or more xylanases claim 15 , one or more beta-xylosidases claim 15 , and one or more L-arabinofuranosidases.1720-. (canceled)21. A host cell comprising an expression vector comprising a nucleic acid in operable combination with a regulatory sequence claim 15 , the nucleic acid encoding a recombinant polypeptide comprising an amino acid sequence that is at least 55% identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:3 claim 15 , wherein the polypeptide has beta-mannanase activity.22. The host cell of claim 21 , wherein the host cell is a bacterial cell or a fungal cell.23. A composition comprising the host cell of and a ...

Detergent Composition

The present invention concerns a detergent comprising a polypeptide having galactanase activity. It further concerns a laundering method and the use of galactanases. The present invention further relates to polypeptides having galactanase activity, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides. 14-. (canceled)5. A detergent composition comprising a polypeptide having endo-beta-1 ,6-galactanase activity and a detergent adjunct ingredient.6Bacillus lentusFusarium. The detergent composition according to claim 5 , wherein the protease is selected from the group consisting of BPN′ claim 5 , subtilisin Novo claim 5 , subtilisin Carlsberg claim 5 , subtilisin 309 claim 5 , subtilisin 147 claim 5 , subtilisin 168 claim 5 , DSM 5483 protease claim 5 , trypsin-like proteases claim 5 , proteases from and variants hereof.7. The detergent composition according to claim 6 , wherein the protease is a protease having at least 80% sequence identity to SEQ ID NO 7.9. A polypeptide having endo-beta-1 claim 6 ,6-galactanase activity claim 6 , selected from the group consisting of:(a) a polypeptide having at least 60% sequence identity to the mature polypeptide of SEQ ID NO: 2;(b) a polypeptide encoded by a polynucleotide that hybridizes under medium stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, or (ii) the full-length complement of (i);(c) a polypeptide encoded by a polynucleotide having at least 60% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1;(d) a variant of the mature polypeptide of SEQ ID NO: 2 comprising a substitution, deletion, and/or insertion at one or more positions; and(e) a fragment of the polypeptide of (a), (b), (c), or (d) that has endo-beta-1,6-galactanase activity.1014-. (canceled)15. A polynucleotide encoding the polypeptide of .1614. A nucleic acid construct or expression vector comprising the polynucleotide of claim operably linked to one or more control ...

SPERM ACTIVATING AGENT AND ACTIVATING METHOD USING SAME

The present invention relates to an agent for activating mammalian sperm and a method for activating sperm by use of the activating agent. More specifically, the present invention relates to a sperm activating agent containing endo-β-galactosidase and/or FGF, which accelerate motility of mammalian sperm, for use in in-vitro fertilization and artificial insemination by husband and a sperm activating method by adding endo-β-galactosidase and/or FGF. 1. A sperm-activating agent comprising endo-β-galactosidase and/or FGF.2. The sperm-activating agent according to claim 1 , wherein the FGF is bFGF.3. A sperm-activating method comprising the step of adding endo-β-galactosidase and/or FGF to isolated sperm.4. The sperm-activating method according to claim 3 , wherein the FGF is bFGF. The present invention relates to an agent for activating mammalian sperm and a method for activating sperm by using the activating agent. More specifically, the present invention relates to a sperm activating agent containing endo-β-galactosidase and/or FGF, which accelerate motility of mammalian sperm, for use in in-vitro fertilization and artificial insemination and a sperm activating method by adding endo-β-galactosidase and/or FGF.After ejaculation, mammalian sperm is activated for motility acquisition and capacitation. The activation process is a reaction, which takes place before the acrosome reaction or before sperm encounters egg and is a reversible reaction depending upon a decapacitation factor (DF) contained in the seminal fluid.Motility acquisition of sperm is a phenomenon required for enabling the acrosome reaction of sperm. Furthermore, motility acquisition and capacitation simultaneously occur and these two sperm activation phenomena both are essential for fertilization. Capacitation is defined as a series of biochemical reactions caused by removal of a decapacitation factor. To cause these two phenomena, calcium and glucose are conceivably required.A ketone body induces an ...

FUNGAL HIGH-LEVEL PROTEIN PRODUCTION SYSTEM

Provided are cells having an increased protein production characterized in that said cell comprises modified SUMOylation, a process for producing such a cell or expression system and the use of such a cell in producing a protein of interest. 1. A modified cell having increased protein production , wherein said cell has been modified to result in altered SUMOylation.2. The modified cell of claim 1 , wherein the increase in protein production is an increase of overall protein production of at least 1.1 fold as compared to the total protein production of the parental cell that lacks the modification of SUMOylation.3. The modified cell of claim 1 , wherein the increase in protein production is an increase of production of a protein of interest at least 1.1 fold as compared to the production of said protein by the parental cell that lacks the modification of SUMOylation.4. The modified cell of any one of - claim 1 , wherein the cell has been modified by genetic modification to result in altered SUMOylation.5. The modified cell of claim 4 , wherein the genetic modification is a point mutation claim 4 , insertion and/or deletion.6. The modified cell of or wherein the genetic modification is a targeted genetic modification.7. The modified cell of any one of - claim 4 , wherein SUMOylation has been modified by genetic modification of at least one gene encoding an endogenous protein of the SUMOylation machinery.8. The modified cell of claim 7 , wherein the genetic modification is a modification of an expression regulating sequence or the coding sequence.9. The modified cell of any one of the preceding claims claim 7 , wherein SUMOylation has been modified by reducing Ubc9 production and/or activity.10. The modified cell of claim 9 , wherein Ubc9 has been modified by a gene disruption located in the promoter sequence of the ubc9 gene.11M. thermophila].. The modified cell of any one of or claim 9 , wherein the ubc9 gene has a wild type counterpart that has at least 50% sequence ...

Detergent Compositions

The present invention concerns a detergent comprising a polypeptide having galactanase activity. It further concerns a laundering method and the use of galactanases. The present invention further relates to polypeptides having galactanase activity, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides. 114-. (canceled)15. A polynucleotide encoding a polypeptide having endo-beta-1 ,6-galactanase activity , selected from the group consisting of:(a) a polypeptide having at least 60% sequence identity to the mature polypeptide of SEQ ID NO: 2;(b) a polypeptide encoded by a polynucleotide that hybridizes under medium stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, or (ii) the full-length complement of (i);(c) a polypeptide encoded by a polynucleotide having at least 60% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1;(d) a variant of the mature polypeptide of SEQ ID NO: 2 comprising a substitution, deletion, and/or insertion at one or more positions; and(e) a fragment of the polypeptide of (a), (b), (c), or (d) that has endo-beta-1,6-galactanase activity.16. A nucleic acid construct or expression vector comprising the polynucleotide of operably linked to one or more control sequences that direct the production of the polypeptide in an expression host.17. A recombinant host cell comprising the polynucleotide of operably linked to one or more control sequences that direct the production of the polypeptide.18. A method of producing a polypeptide having endo-beta-1 claim 15 ,6-galactanase activity claim 15 , selected from the group consisting of:(a) a polypeptide having at least 60% sequence identity to the mature polypeptide of SEQ ID NO: 2;(b) a polypeptide encoded by a polynucleotide that hybridizes under medium stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1, or (ii) the full-length complement of (i);(c) a polypeptide encoded by a ...

AGAROOLIGOSACCHARIDE HYDROLASE AND METHOD FOR PRODUCING 3,6-ANHYDRO-L-GALACTOSE AND GALACTOSE FROM AGAROSE BY USING SAME

The present invention relates to agarooligosaccharide hydrolase and a method for producing 3,6-anhydro-L-galactose and galactose from agarose by using the same. More specifically, the production yield of 3,6-anhydro-L-galactose and galactose from agarose, that is, the saccharification yield, is improved by using β-agarooligosaccharide hydrolase having an agarotriose hydrolytic activity. 1. A composition for agarose saccharification comprising:an agarase;a β-agarooligosaccharide hydrolase having hydrolytic activity for agarotriose and represented by an amino acid sequence of SEQ ID NO:1; andan α-neoagarobiose hydrolase.2. The composition of claim 1 , wherein the agarase is represented by an amino acid sequence of SEQ ID NO: 3.3. The composition of claim 1 , wherein the β-agarooligosaccharide hydrolase hydrolyzes agarotriose into D-galactose and neoagarobiose.4Vibrio. The composition of claim 1 , wherein the β-agarooligosaccharide hydrolase originates from sp. EJY3.5. The composition of claim 1 , wherein the α-neoagarobiose hydrolase is represented by an amino acid sequence of SEQ ID NO: 4.6. The composition of claim 1 , wherein the composition for agarose saccharification produces 3 claim 1 ,6-anhydro-L-galactose and D-galactose from agarose either by reacting pretreated agarose with an enzyme mixture of an agarase claim 1 , a β-agarooligosaccharide hydrolase claim 1 , and an α-neoagarobiose hydrolase claim 1 , or by allowing the agarase claim 1 , the β-agarooligosaccharide hydrolase claim 1 , and the α-neoagarobiose hydrolase to react sequentially with the pretreated agarose.7. A method of saccharifying agarose by a reaction between a substrate and the composition of claim 1 , wherein the substrate is selected from the group consisting of agarose claim 1 , agarotriose claim 1 , and neoagarobiose.8. The method of claim 7 , wherein the reaction is carried out in a temperature range of 20 to 40° C. under conditions of 0 to 200 rpm for a duration ranging from 30 minutes ...

CELL SUITABLE FOR FERMENTATION OF A MIXED SUGAR COMPOSITION

The present invention relates to a cell suitable for production of one or more fermentation product from a sugar composition comprising glucose, galactose, arabinose and xylose, wherein the cell comprises two to fifteen copies of one or more xylose isomerase gene or two to fifteen copies of one or more xylose reductase and xylitol dehydrogenase, and two to ten copies of araA, araB and araD, genes, wherein these genes are integrated into the cell genome. 1Saccharomyces cerevisiae. A transformed cell suitable for producing at least one fermentation product from a sugar composition comprising glucose , galactose , xylose , arabinose and mannose , wherein said cell comprises:(a) two to fifteen copies of at least one xylose isomerase gene or two to fifteen copies of at least one xylose reductase and xylitol dehydrogenase, and(b) from two to ten copies of L-arabinose isomerase (araA), L-ribulokinase (arae), and L-ribulose-5-phosphate 4-epimerase (araD) genes,wherein said genes are integrated into the cell genome,and wherein said cell comprises a disruption or deletion of the GAL80 (transcriptional repressor) gene.2. The yeast cell according to claim 1 , wherein said cell is capable of converting at least 90% of glucose claim 1 , xylose arabinose claim 1 , galactose and mannose available claim 1 , into a fermentation product.3. The yeast cell according to claim 1 , wherein said cell comprises overexpressed PPP-genes TAL1 (transaldolase) claim 1 , TKL1 (transketolase) claim 1 , RPE1 (ribulose-phosphate 3-epimerase) claim 1 , and RKI1 (ribulose-5-phosphate isomerase).4. The yeast cell according to claim 1 , wherein said cell comprises a XKS1 (xylulose kinase) gene.5. The yeast cell according to claim 1 , wherein an aldose reductase gene is deleted.6. The yeast cell according to claim 1 , wherein all genes exogenous to said cell are integrated into the genome of said cell.7. A yeast cell according to claim 1 , wherein genes have been introduced in said cell by introduction ...

SIALYLATED GLYCOPROTEIN COMPOSITONS AND USES THEREOF

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders. 127-. (canceled)28. A method for treating mucopolysaccharidosis type 7 , comprising administering a recombinant β-glucuronidase , wherein the recombinant β-glucuronidase is administered at a dose of 0.5 mg/kg to 12 mg/kg , and wherein the recombinant β-glucuronidase has a sialylation content of at least 0.7 mol/mol of the recombinant β-glucuronidase.29. The method of claim 28 , wherein the recombinant glycoprotein has a sialylation content of at least 1 mol/mol and a level of M6P moieties of at least 10 mol % of the total glycan of the recombinant glycoprotein.30. The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of at least about 0.5 mg/kg.31. The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of at about 1 mg/kg to about 8 mg/kg.32. The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of at about 2 mg/kg to about 6 mg/kg.33. The method of claim 28 , wherein the recombinant β-glucuronidase is administered at a dose of at about 4 mg/kg.34. The method of claim 28 , wherein the recombinant β-glucuronidase is administered weekly.35. The method of claim 28 , wherein the recombinant β-glucuronidase is administered every other week.36. The method of claim 28 , wherein the recombinant β-glucuronidase is administered intravenously.37. The method of claim 28 , wherein the recombinant β-glucuronidase is administered by continuous infusion.38. The method of claim 28 , wherein the regimen of recombinant β-glucuronidase is administered concurrently with or following antihistamine therapy.39. The method of claim 28 , wherein the recombinant β-glucuronidase is administered to a human.40. The method of claim 28 , wherein the recombinant β-glucuronidase has a sialylation content of about 0.8 mol/mol.41. The method of claim 28 ...

Cleaning compositions containing dispersins i

Cleaning compositions may include polypeptides having hexosaminidase activity. The cleaning compositions may include a polypeptide having one or more of the motif(s) GXDE (SEQ ID NO 27), [EQ][NRSHA][YVFL][AGSTC][IVLF][EAQYN][SN] (SEQ ID NO: 28), HFHIGG (SEQ ID NO: 29), FLHLHF (SEQ ID NO: 30) or DHENYA (SEQ ID NO: 31), or combinations thereof. The cleaning compositions may be or include laundry detergents, fabric finishers, acidic cleaning agents, neutral cleaning agents, alkaline cleaning agents, hand dishwashing agents, automatic dishwasher compositions, or combinations thereof.

Sialylated glycoprotein compositions and uses thereof

The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

LACTASE SOLUTION AND DAIRY PRODUCT USING SAME

[Problem] To provide a lactase solution having excellent thermal stability. 1. A lactase solution comprising a lactase fraction having a molecular weight of about 120 kDa measured by SDS polyacrylamide gel electrophoresis in a ratio of 20% or more.2. The lactase solution according to claim 1 , wherein the sum of the ratio of the about 120-kDa lactase fraction and a ratio of a lactase fraction having a molecular weight of about 80 kDa measured by SDS polyacrylamide gel electrophoresis is 30% or more.3. The lactase solution according to claim 1 , wherein a ratio of a lactase fraction having a molecular weight of about 50 kDa measured by SDS polyacrylamide gel electrophoresis is 70% or less.4. The lactase solution according to claim 1 , wherein a value obtained by dividing the sum of the ratio of the about 120-kDa lactase fraction and the ratio of the about 80-kDa lactase fraction by the ratio of the lactase fraction having the molecular weight of about 50 kDa measured by SDS polyacrylamide gel electrophoresis is 0.5 or more.5. The lactase solution according to claim 1 , for use in producing dairy products.6. A dairy product comprising the lactase solution according to .7. A method for treating a raw material milk claim 1 , comprising adding to a raw material milk the lactase solution according to claim 1 , and decomposing lactose contained in the raw material milk at 1 to 60° C.8. A method for producing a lactase solution claim 1 , comprisinga culture step in which a microorganism is cultured,a collection step in which the lactase is collected from the culture product obtained in the culture step, anda purification step in which the lactase collected in the collection step is purified, whereinthe purification step includes one or more cycles of:a step in which a salting-out treatment and a desalting treatment are carried out.9. The method for producing the lactase solution according to claim 8 , wherein the salting-out treatment comprises;a saturation step in which to ...

Novel β-agarase, process for producing the same and use thereof

Detergent compositions with galactanase

The present invention relates to polypeptides having endo-beta-1-6-galactanase enzyme activity, detergent composition comprising such polypeptides and uses of the composition and/or polypeptide in methods of washing, such as laundering of textiles.

CLEANING COMPOSITIONS CONTAINING DISPERSINE I

Die vorliegende Erfindung betrifft spezifische Reinigungszusammensetzungen, umfassend Polypeptide mit Hexosaminidaseaktivität. Die Erfindung bezieht sich ferner auf die Verwendung der Zusammensetzungen sowie auf Verfahren zum Verwenden der Zusammensetzungen. The present invention relates to specific cleaning compositions comprising polypeptides having hexosaminidase activity. The invention further relates to the use of the compositions and to methods of using the compositions.

Cleaning compositions containing dispersins i

The present invention relates to specific cleaning compositions comprising polypeptides having hexosaminidase activity. The invention further relates to the use of said compositions as well as methods of using said compositions.

Compositions comprising beta-mannanase and methods of use

The present compositions and methods relate to a beta-mannanase from Paenibacillus macerans , polynucleotides encoding the beta-mannanase, and methods of make and/or use thereof. Formulations containing the beta-mannanase are suitable for use in hydrolyzing lignocellulosic biomass substrates, especially those comprising a measurable level of galactoglucomannan (GGM) and/or glucomannan (GM).

Nucleic acids of aspergillus fumigatus encoding industrial enzymes and methods of use

The present invention provides nucleotide sequences of Aspegillus fumigatus that encode proteins which exhibit enzyme activities. Vectors, expression constructs, and host cells comprising the nucleotide sequences of the enzyme genes are also provided. The invention further provides methods for producing the enzymes, and methods for modifying the enzymes in order to improve their desirable characteristics. The activities displayed by the enzymes of the invention include those of a tannase, cellulase, glucose oxidase, glucoamylase, phytase, β-galactosidases, invertase, lipase, α-amylase, laccase, polygalacturonase or xylanase. The enzymes of the invention can be used in a variety of industrial processes. Enzymatically active compositions in various forms as well as antibodies to the enzymes and fragments thereof, are also provided.

ENZYM WITH GALACTANASE ACTIVITY

Cell suitable for fermentation of a mixed sugar composition

Multiple biomarker set for breast cancer diagnosis, method of detecting the same, and diagnosis kit for breast cancer using antibody against the same

본 발명은 아포리포단백질 C1, 아포리포단백질 (a), 신경세포 접착분자 L1 유사 단백질, 탄산탈수효소 1, 및 파이브로넥틴 중 2가지 이상의 단백질 마커로 이루어진 유방암 진단용 바이오마커 세트, 상기 바이오마커 세트를 다중 반응 모니터링 방법을 통해 혈액 시료에서 검출하는 방법, 상기 바이오마커 세트의 단백질에 특이적인 항체를 포함하는 유방암 진단키트, 및 항원-항체 결합반응을 이용하여 혈액 내에서 상기 마커 세트의 단백질을 검출하는 방법에 관한 것이다. MRM법 또는 항원-항체 결합반응을 통해 혈액 시료에서 본 발명의 유방암 진단용 단백질 마커 세트를 검출하는 방법 및 진단 키트는 단일 마커를 이용한 진단 방법에 비하여 진단의 민감도 및 정확도가 월등히 높을 뿐만 아니라 환자의 혈액을 이용하여 매우 간편하게 유방암을 진단할 수 있어 유방암의 조기 진단에 유용하게 사용될 수 있다.　 The present invention relates to a biomarker diagnostic biomarker set comprising two or more protein markers of apolipoprotein C1, apolipoprotein (a), neuronal cell adhesion molecule L1-like protein, carbonic anhydrase 1 and fibronectin, A method for detecting a protein in a blood sample through a multiple reaction monitoring method, a breast cancer diagnostic kit comprising an antibody specific to the protein of the biomarker set, and a method for detecting the protein of the marker set in the blood using an antigen- . The method and kit for detecting the breast cancer diagnostic protein marker of the present invention in a blood sample through the MRM method or the antigen-antibody conjugation reaction are superior in sensitivity and accuracy of diagnosis as compared with the diagnostic method using a single marker, Can be used for early diagnosis of breast cancer because it can diagnose breast cancer very easily.

High level protein production system for fungi

提供了具有增加的蛋白质生产的细胞，其特征在于所述细胞包含经修饰的SUMO化；用于产生此类细胞或表达系统的方法；以及此类细胞在产生目的蛋白质中的用途。

Polypeptides of strain bacillus SP. P203

A new strain Bacillus sp. P203 (Bacillus plakortiensis ) is disclosed. Isolated mature functional polypeptide which is obtainable from the bacterium strain Bacillus sp. P203 deposited under accession number DSM 17419 are disclosed.

Polypeptides of strain Bacillus sp. P203

A new strain Bacillus sp. P203 ( Bacillus plakortiensis ) is disclosed. Isolated mature functional polypeptide which is obtainable from the bacterium strain Bacillus sp. P203 deposited under accession number DSM 17419 are disclosed.

Polypeptides of strain bacillus SP. P203

A new strain Bacillus sp. P203 ( Bacillus plakortiensis ) is disclosed. Isolated mature functional polypeptide which is obtainable from the bacterium strain Bacillus sp. P203 deposited under accession number DSM 17419 are disclosed.

Pheromone - inducible yeast promoter

A yeast promoter inducible by the appropriate pheromone and a method of expressing a gene of interest in substantial quantities by placing it under the control of the inducible promoter. DNA encoding a protein of interest is fused or linked to a pheromone - inducible yeast promoter, such as the FUSI or the FUS2 promoter, and the fusion is inserted onto a high copy vector; the resulting product is introduced into wild type yeast cells. Stimulation of these yeast cells by the appropriate pheromone results in induction of transcription of the yeast promoter and expression of the protein of interest in substantial quantities.

Enzymatic method for neoagarobiose or neoagarotetraose production from agarose using a new beta-agarase

본 발명은 신규한 베타-아가레이즈 생산 유전자를 이용한 네오아가로바이오스 또는 네오아가로테트라오스의 효소적 생산방법에 관한 것으로, 본 발명에 따른 방법은 직접 네오아가로바이오스(neoagarobiose) 또는 네오아가로테트라오스(neoagarotetraose)와 같은 특정한 당류의 형태로 선택하여 분해할 수 있는 장점으로, 이들 산물이 요구되고 있는 식품, 화장품, 의약품 뿐 아니라 바이오 연료의 연료로서 유용하게 사용할 수 있는 장점이 있다. The present invention relates to a novel method for producing neoagarobiose or neoagarotetraose using a novel beta-agarase-producing gene, and a method according to the present invention is a method for directly producing neoagarobiose or neoagarotetraose And can be selectively used in the form of a specific saccharide such as neoagarotetraose. Therefore, these products can be advantageously used as fuels for biofuels as well as foods, cosmetics, and pharmaceuticals in which these products are required.

Enzyme Complex of Expansin-Agarase and Method for Degrading Agar Using The Same

The present invention relates to an expansin-agarase enzyme complex and an agar decomposition method using the same. When the enzyme complex according to the present invention is used, the agar obtained from marine biomass can be efficiently decomposed, so that useful physiologically active substances such as diose, triose and oligosaccharide as well as galactose and glucose necessary for ethanol production can be obtained.

Method for delivering beneficial compositions to hair follicles

The present invention describes a method for targeted and specific delivery of beneficial compounds, including hair dyes, melanin, proteins, and nucleic acids for gene therapy, to hair follicle cells using liposomes encapsulating the beneficial compound. Particularly preferred methods describe delivery of hair dyes, melanin or tyrosinase to the hair follicle for the purpose of improving hair color or condition, either by encapsulating the compound in liposomes, or by encapsulating a nucleic acid capable of expressing the protein in liposomes. Also described are liposome compositions for practising the methods.

Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same

本发明涉及琼胶寡糖水解酶及一种通过利用该琼胶寡糖水解酶从琼脂糖中生成3,6‑脱水‑L‑半乳糖和半乳糖的方法。更具体地，通过使用对琼脂三糖具有水解活性的β‑琼胶寡糖水解酶，提高来自琼脂糖中的3,6‑脱水‑L‑半乳糖和半乳糖的产率，即糖化率。

Novel DNA fragment, recombinant vector containing the same, transformant transformed therewith and utilization of the same

本发明涉及单独含有特定基因调节区域的DNA片段、或含有该基因调节区域与编码信号肽的基因的DNA片段、含有该DNA片段的重组载体、含有该重组载体的转化体以及使用该转化体制备重组蛋白质的方法。根据本发明，可以与重组蛋白质的种类无关地大量且有效地生产蛋白质。

Methods for delivering beneficial formulations to hair follicles

Agarase and gene thereof

本发明涉及可用于有效地生产琼脂寡糖、从琼脂糖凝胶中有效地提取核酸等物质的、具有琼脂糖酶活性的多肽、所述多肽的氨基酸序列、编码所述多肽的基因、所述多肽的生产方法以及琼脂寡糖的生产方法和从琼脂糖凝胶提取核酸等物质的方法。

Method for producing lactase-containing composition

A beta-agarase AgaJ11 from Gayadomonas joobiniege G7 and use thereof

본 발명은 가야도모나스 주비니에게 G7 유래 베타-아가레이즈 AgaJ11 및 이의 이용에 관한 것으로, 구체적으로 가야도모나스 주비니에게 G7으로부터 동정되어 이종균주에서 과발현이 가능하며 아가로오스를 분해하여 네오아가로올리고당을 생성할 수 있고 낮은 pH에서도 효소활성을 안정적으로 나타내는 베타-아가레이즈 AgaJ11 및 이를 이용하는 방법에 관한 것이다. 본 발명에 따르면 가야도모나스 주비니에게 G7 유래 베타-아가레이즈 AgaJ11를 이용하여 아가로오스로부터 산업상 매우 유용한 네오아가로올리고당을 효율적으로 생산할 수 있으며, 아가로오스를 저분자로 분해하는 방법이 필요한 분야에서도 유용하게 이용할 수 있다. 특히 본 발명에 따르면 AgaJ11은 낮은 pH 조건에서 우수한 베타-아가레이즈 활성을 나타내기 때문에 본 발명에서 제공하는 방법, 조성물 및 키트는 다양한 조건이 요구되는 산업 분야에서 보다 유용하게 이용될 수 있을 것으로 기대되며, 또한 본 발명에서 제공하는 벡터, 형질전환체 및 베타-아가레이즈 대량생산방법을 이용하면 이종숙주세포를 사용한 과발현 시스템을 통해 베타-아가레이즈를 효율적으로 생산할 수 있다.

The high-level protein production system of fungi

提供了具有增加的蛋白质生产的细胞，其特征在于所述细胞包含经修饰的SUMO化；用于产生此类细胞或表达系统的方法；以及此类细胞在产生目的蛋白质中的用途。

ARTIFICIAL PROMOTER FOR THE EXPRESSION OF PROTEINS IN YEAST.

L'invention concerne un promoteur artificiel pour l'expression de protéines dans la levure qui comporte: - une sous-séquence en amont de l'élément TATA de la séquence du promoteur du gène GAL7 de Saccharomyces cerevisiae, qui comporte les séquences d'activation amont UAS1 et UAS2. - une sous-séquence de la séquence d'un promoteur ADH2 comportant l'élément TATA et la région d'initiation de la transcription. Application: Obtention de protéines notamment, d'urate oxydase. The invention relates to an artificial promoter for the expression of proteins in yeast which comprises: - a subsequence upstream of the TATA element of the promoter sequence of the GAL7 gene of Saccharomyces cerevisiae, which comprises the activation sequences upstream UAS1 and UAS2. - a sub-sequence of the sequence of an ADH2 promoter comprising the TATA element and the transcription initiation region. Application: Obtaining proteins, in particular urate oxidase.

Method for delivering beneficial compositions to hair follicles

The present invention describes a method for targeted and specific delivery of beneficial compounds including hair dyes, melanin, proteins, and nucleic acids for gene therapy, to hair follicle cells using liposomes encapsulating the beneficial compound. Particularly preferred methods describe delivery of hair dyes, melanin or tyrosinase to the hair follicle for the purpose of improving hair color or condition, either by encapsulating the compounds in liposomes, or by encapsulating a nucleic acid capable of expressing the protein in liposomes. Also described are liposome compositions for practising the methods.

GENES CODING BETA-AGARASES AND THEIR USE FOR THE PRODUCTION OF AGARS BIODEGRADATION ENZYMES

Patent FR2492404B1

Duodenal enzyme complex - by 33 per cent aqs acetone extraction of unmilled duodenum

Prepn. of stable enzyme complex from the duodenum by contacting fresh or frozen duodenum with aq. acetone (25-40% by vol) the rato of duodenum to aq. acetone being such that the enzymes are not pptated. the sepg. the duodenum residue from the soln. of enzymes. Almost all the enzyme activity of the duodenum is recovered without denaturation. The prod. is used in treating diarrhoea due to deficiency of duodenal enzymes. Pref. the duodenum is chopped but not milled before extn. (loss of activity follows milling). A pref. extn. uses 1.8 vol. of 33% acetone at pH 6-7 (below pH 6, enterokinase is inactivated). Above pH 7 autodigestion of the proteins is possible.

GENES CODING BETA-AGARASES AND THEIR USE FOR THE PRODUCTION OF AGARS BIODEGRADATION ENZYMES

The invention concerns the new strain Cytophaga drobachiensis filed in the DSMZ Collection (Deutsche Sammlung von Mikroorganismen und Zellkulturen Gmb-H) on May 8 1998 under number DSM 12170, the gene agaA coding for a beta -agarase and having the SEQ ID NO:1, the gene agaB coding for a beta -agarase and having the SEQ ID NO:3, said genes coding for a DSM 12170 Cytophaga drobachiensis beta -agarase, and the particular nucleic acid sequence of the gene agaA coding for a particular AgaA' peptide fragment which has preserved beta -agarase activity, and having the SEQ ID NO:5, and the DSM 12170 C. drobachiensis AgaA protein having the SEQ ID NO:2, the DSM 12170 C. drobachiensis having the SEQ ID NO:4 and said DSM 12170 C. drobachiensis AgaA' peptide fragment having the SEQ ID NO:6. The invention is applicable to agar biodegradation.

Sialylated glycoprotein composition and use thereof

Method of producing endo-–-n-acetylgalactos-aminidase from microorganisms

The method is disclosed of providing endo-.alpha.-N-acetyl-galactosaminidase (endo-.alpha.-GalNAcase) from a microorganism belonging to the genus Alcaligenes. The endo-.alpha.-GalNAcase is very useful in the analysis of the structure and function of mucin-type sugar chains of glycoproteins, since it is an enzyme capable of cleaving O-glycosidic linkages of sugar chains of glycoproteins, releasing the sugar chain from the protein.

Patent FR2252085B1

Modified proteins containing controllable intermediate sequences and methods for their preparation

ARTIFICIAL PROMOTER FOR THE EXPRESSION OF PROTEINS IN YEAST.

Stable, polyenzyme complex - extracted from plant tissue in a single operation

Polyenzmatic complexes extracted from plants, in which there is no inhibitory interaction between the components and in which all the enzymes in the intermediate and final products are obtained simultaneously either during or at the end of a single manufacture. The complex contains 6 enzymes. The compsn. is made simply without need for separate prepn. of individual enzymes, then mixing of the products.

Enzyme Complex Containing Beta agarase, Kappa carrageenase and Anhydro-galactosidase and Use thereof

본 발명은 키메릭 카파-카라기나아제 및 키메릭 베타-아가레이즈 및 키메릭 무수갈락토시다아제를 함유하는 효소 복합체에 관한 것으로, 더욱 자세하게는 베타-아가레이즈와 엔도-β-1,4-글루카나아제-B의 도커린 모듈이 융합된 키메릭 베타-아가레이즈, 카파-카라기나아제와 엔도-β-1,4-글루카나아제-B의 도커린 모듈이 융합된 키메릭 카파-카라기나아제, 무수갈락토시다아제와 엔도-β-1,4-글루카나아제-B의 도커린 모듈이 융합된 키메릭 무수갈락토시다아제 및 소형 셀룰로즈-결합 단백질 A가 결합 되어 있는 효소 복합체 및 이를 이용한 홍조류 바이오매스의 분해 방법에 관한 것이다. 본 발명에 따르면, 아가 분해 생산물 제조에 있어서 물리적, 화학적 전처리 공정에 의존하였던 기존의 방식에서 엔자임을 이용한 분해 공정을 도입함으로써 뛰어난 효율성, 생산물의 제어, 간편한 활용성, 저비용 고효율의 친환경적 분해 시스템을 이용하여 해양조류부터 가치 있는 생산물을 효율적으로 전환하는데 크게 기여할 것으로 기대된다.

Galactosidalse with alpha-galactosyltransferase activity

Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-l-galactose and galactose from agarose by using same

The present invention relates to agarooligosaccharide hydrolase and a method for producing 3,6-anhydro-L-galactose and galactose from agarose by using the same. More specifically, the production yield of 3,6-anhydro-L-galactose and galactose from agarose, that is, the saccharification yield, is improved by using β-agarooligosaccharide hydrolase having an agarotriose hydrolytic activity.

Polypeptides having transgalactosylating activity

The present invention relates to polypeptides, specifically polypeptides having transgalactosylating activity and nucleic acids encoding these, and their uses in e.g. dairy product.

Process for the production of cells which are capable of converting arabinose

The invention relates to a process for the production of cells which are capable of converting arabinose, comprising the following steps: a)Introducing into a host strain that cannot convert arabinose, the genes AraA, araB and araD, this cell is designated as constructed cell; b)Subjecting the constructed cell to adaptive evolution until a cell that converts arabinose is obtained, c)Optionally, subjecting the first arabinose converting cell to adaptive evolution to improve the arabinose conversion; the cell produced in step b) or c) is designated as first arabinose converting cell; d)Analysing the full genome or part of the genome of the first arabinose converting cell and that of the constructed cell; e)Identifying single nucleotide polymorphisms (SNP's) in the first arabinose converting cell; and f)Using the information of the SNP's in rational design of a cell capable of converting arabinose; g)Construction of the cell capable of converting arabinose designed in step f).

One kind tool heat endurance and halophilic agarase

本发明公开了一种具热稳定性且耐高盐的琼脂水解酶，本发明自微泡菌(Microbulbifer sp.)中发现可水解琼脂的基因，将此基因克隆至大肠杆菌中，可表达出约88kDa大小的蛋白质，此水解琼脂酶在60℃及pH7的条件下可达最优化的水解琼脂效果，并且对于高浓度盐类及金属螯合剂具有相当的耐受性，置于70℃高温下3小时，此琼脂水解酶仍可维持92％以上的活性，分析其水解后的产物为新琼二糖，此种糖类化合物在美容保养品中可作为保湿及美白功效的成分。

A kind of induction marine microorganism fermentation produces the combination inducer of kappa-carrageenan enzyme

本发明涉及一种诱导海洋微生物发酵产κ‑卡拉胶酶的组合诱导物，属于微生物发酵技术领域。所述组合诱导物组成成分按重量份计为0.5~1.5份低聚果糖、1~3份κ‑卡拉胶、0.5~1.5份酵母提取物。以一定配比的低聚果糖、κ‑卡拉胶、酵母提取物作为海洋微生物的产酶诱导物，发酵生产κ‑卡拉胶酶。通过摇瓶振荡发酵48 h，海旋菌（ Thalassospira sp.Fjfst‑332）的κ‑卡拉胶酶活力为351 U/mL，与不添加诱导物时，菌株κ‑卡拉胶酶的酶活54.3 U/mL相比，提高了6.46倍。

liquid lactase compositions

Agarase and gene thereof

Production of efficiently producing agaro-oligosaccharide; a polypeptide having an agarase activity which is usable in, for example, efficiently extracting a substance such as a nucleic acid from an agarose gel; the amino acid sequence of the polypeptide; a gene encoding the polypeptide; a process for producing the polypeptide; a process for producing agaro-oligosaccharide; and a process for extracting a substance such as a nucleic acid from an agarose gel.

An enzyme with galactanase activity

The present invention relates to an enzyme with galactanase activity, a DNA construct encoding the enzyme with galactanase activity, a method of producing the enzyme, an enzyme composition comprising said enzyme with galactanase activity, and the use of said enzyme and enzyme composition for a number of industrial applications.

Process for the production of cells which are capable of converting arabinose.

La presente invención se relaciona con un proceso para producir células capaces de convertir arabinosa que comprende las siguientes etapas: a) introducir los genes araA, araB y araD en una cepa hospedera que no puede convertir arabinosa, donde la célula resultante se conoce como una célula construida; b) someter la célula construida a una evolución adaptativa hasta obtener una célula capaz de convertir arabinosa; c) opcionalmente, someter la primera célula capaz de convertir arabinosa a una evolución adaptativa para mejorar la conversión de la arabinosa, donde la célula que se obtiene en el paso b) o c) se conoce como la primera célula capaz de convertir arabinosa; d) analizar la totalidad o una parte del genoma de la primera célula capaz de convertir arabinosa y de la célula construida; e) identificar los polimorfismos de un solo nucleótido (SNP) en la primera célula capaz de convertir arabinosa; y f) usar la información de los SNP en el diseño racional de una célula capaz de convertir arabinosa; g) construir la célula capaz de convertir arabinosa diseñada en el paso f).

Patent FR2236938B1

Agarase and gene for it

DEVELOPMENT OF TECHNOLOGY FOR INDUCING AN OVEREXPRESSION OF β-AGARASE DagA ENZYME

본 발명은 β-아가라아제(β-agarase) Dag A 효소가 과발현 되어 있는 형질전환 방선균 균주 및 상기 균주를 개발하는 방법에 관한 것이다. 또한 상기 형질전환 방선균 균주를 이용하여 인 비보( in vivo )에서 네오아가로헥사오스 또는 네오아가로테트라오스를 생산하는 방법에 관한 것이다. The present invention relates to a transformed actinomycetes strain in which the enzyme β-agarase Dag A is overexpressed and a method for developing the strain. It also relates to a method of producing neo-agarohexaose or neo-agarotetraose in vivo using the transformed actinomycetes strain.

Artificial promoter for the expression of proteins in yeast

Cellulose binding fusion proteins

Novel polypeptide compositions and methods for their use are provided comprising fusion proteins capable of binding to a polysaccharide matrix. The compositions may be synthesized or prepared by recombinant DNA technology.

Cellulose binding fusion proteins

Novel polypeptide compositions and methods for their use are provided comprising fusion proteins cap-able of binding to a polysaccharide matrix. The compo-sitions may be synthesized or prepared by recombinant DNA technology.

galactosity with alpha-galactosyltransferase activity

GALACTOSIDASE COM ATIVIDADE ALFA-GALACTOSlLTRANSFERASE. A presente invenção refere-se a <225>-galactosidase com atividade trans-galactosilaçao isolada de Bifidobacterium bifidum. A <225>-galactosidase é capaz de converter lactose numa mistura de oligossacarídeos que são ligados na posição <225>, e produzem, inesperadamente o dissacarídeo a-ligado, galactobiose. A mistura pode ser incorporada em numerosos produtos alimentares ou alimentos para animais com a finalidade de melhorar a saúde intestinal promovendo o crescimento de bifidobactérias no intestino, e reprimindo o crescimento da microflora patogênica. GALACTOSIDASE WITH ALPHA-GALACTOSLTRANSFERASE ACTIVITY. The present invention relates to β-galactosidase with isolated transgalactosylation activity of Bifidobacterium bifidum. The β-galactosidase is capable of converting lactose into a mixture of oligosaccharides which are bound at the β position, and unexpectedly produce the β-linked disaccharide, galactobiose. The mixture may be incorporated into numerous food or feed products for the purpose of improving intestinal health by promoting the growth of bifidobacteria in the intestine, and by suppressing the growth of pathogenic microflora.

A NOVEL IRON-DEPENDENT GH16 β-AGARASE, AGAH92 FROM PSEUDOALTEROMONAS SP. H9

The present invention relates to a novel iron-dependent GH16 β-agarase AgaH92 derived from Pseudoalteromonas sp. H9, and specifically, to β-agarase which is identified from a strain of Pseudoalteromonas sp. H9, allows overexpression in a hetero strain, has thermal stability, and recognizes β-combination of agar so neoagaro-oligosaccharide can be generated. According to the present invention, the β-agarase is greatly effective for decomposing agar into small molecules, can be massively produced by an overexpression system using a hetero host cell, and is highly stable even against heat. Therefore, the β-agarase can be highly practically used with different enzymes in the field of industry to produce various compounds or energy by decomposing or converting agar. Furthermore, in the case of using the β-agarase in the present invention, effective neoagaro-oligosaccharides such as neoagarotetraose or neoagarohexaose can be efficiently produced from agar.

Protein having lactase activity, gene encoding the protein, recombinant vector containing the gene, transformant, production method and use thereof

Enzyme with galactanase activity

本发明涉及一种具有半乳聚糖酶活性的酶、编码具有半乳聚糖酶活性的酶的DNA构建体、产生所说酶的方法、含有所说的具有半乳聚糖酶活性的酶的酶组合物、含有所说的半乳聚糖酶的去垢剂组合物、所说的酶和酶组合物在许多工业上的用途。

Agarase and its genes

効率の良いアガロオリゴ糖の製造、効率の良いアガロースゲルよりの核酸等の物質の抽出等の使用することの出来るアガラーゼ活性を有するポリペプチド、該ポリペプチドのアミノ酸配列、該ポリペプチドをコードする遺伝子、該ポリペプチドの製造方法、ならびにアガロオリゴ糖の製造方法およびアガロースゲルよりの核酸等の物質の抽出方法。 A polypeptide having an agarase activity that can be used for efficient production of agarooligosaccharides, extraction of substances such as nucleic acids from an efficient agarose gel, an amino acid sequence of the polypeptide, a gene encoding the polypeptide, A method for producing the polypeptide, a method for producing agarooligosaccharide, and a method for extracting a substance such as nucleic acid from an agarose gel.

Detergent composition

The present invention concerns a detergent comprising a polypeptide having galactanase activity. It further concerns a laundering method and the use of galactanases. The present invention further relates to polypeptides having galactanase activity, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides.